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ABSTRACT 
 
Glucagon-like peptide-1 (GLP-1) synthetic analog therapies are prescribed 
for type 2 diabetes due to their effects on insulin and glucagon secretion, and 
glycemic control. Recent studies also suggest that they may have cardiovascular 
benefits; however, the mechanism responsible for this is unknown. To examine 
this question, we evaluated the effects of GLP-1 and the GLP-1 synthetic analog, 
liraglutide on cell signaling and function in human aortic endothelial cells 
(HAECs). The results indicate that both agents inhibit TNFα and LPS induced 
cellular adhesion molecule expression and monocyte adhesion. They also show 
that incubation with 30pM GLP-1 and 100nM liraglutide stimulates an immediate 
increase in intracellular calcium, which activates calcium/calmodulin-dependent 
protein kinase kinase β (CaMKKβ). This in turn led to a 2.5 fold increase in the 
phosphorylation of both AMP-activated protein kinase (AMPK) and 
viii 
calcium/calmodulin-dependent protein kinase 1 (CaMK1) within 5 minutes. In 
addition both GLP-1 and liraglutide caused a 2-fold increase in the 
phosphorylation of the downstream AMPK/CaMK1 targets: endothelial nitric 
oxide synthase (eNOS) and cAMP response element-binding protein (CREB). 
Inhibition of CaMKKβ with STO-609 (0.5ug/mL) blocked the phosphorylation of 
both AMPK and CaMK1, confirming its pivotal role. Incubation of the HAECs for 
three hours with lipopolysaccharide (LPS, 2ug/mL) and TNFα (10ng/mL) 
increased the expression of vascular cell adhesion molecule-1 (VCAM-1) and E-
selectin by 5 and 2 fold, respectively. Comparable increases in THP-1 monocyte 
adhesion to the HAECs, a putative initiating event in atherogenesis, also 
occurred. Pre-incubation for one hour with either GLP-1 or liraglutide inhibited 
these events. Likewise, pre-incubation with the CaMKK inhibitor STO-609, or use 
of lentivirus shRNA to knock down AMPK, blocked the inhibitory effects of both 
GLP-1 and liraglutide on monocyte adhesion. These results suggest that the 
recently observed cardiovascular benefits of GLP-1 and liraglutide could be 
mediated by their effects on CaMKKβ, AMPK and CaMK1 activation, which lead 
to decreased adhesion molecule expression and monocyte adhesion in 
endothelial cells. The finding that these effects occur at concentrations of GLP-1 
(30pM) and liraglutide (100nM) observed in vivo also suggests they are 
physiologically relevant.  
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INTRODUCTION:  
The need for treatments that reduce the risk of cardiovascular disease in 
patients with type two diabetes 
According to the American Heart Association, cardiovascular disease and 
stroke are the number one causes of death and disability among people with 
obesity and/or type 2 diabetes mellitus (T2DM). In fact, at least 65% of people 
with T2DM die from heart disease or stroke. Despite numerous options for 
intensive diabetes treatment, large scale prospective studies, such as the United 
Kingdom Prospective Diabetes Program (UKPDS), the Action to Control 
Cardiovascular Disease in Diabetes (ACCORD), and the Veterans Affairs 
Diabetes Trial (VADT), show minimal improvement in cardiovascular disease 
(CVD) with tight glucose control [1]. Additionally, the ACCORD trial highlights that 
current treatments for T2DM may have adverse effects on cardiovascular risk [2]. 
Although treatment with HMG-CoA reductase inhibitor drugs or “statins” can 
reduce CVD incidence by achievement of optimal low density lipoprotein levels, 
overall cardiovascular risk remains high [3]. Therefore, there remains a great 
need for medications that treat T2DM and its increased cardiovascular disease 
risk. 
The discovery of incretins  
The incretins are a class of peptides released from the small intestine, 
identified for their ability to potentiate and increase post-prandial insulin release 
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upon nutrient ingestion. The concept that gut secretions have effects outside of 
the intestine developed in 1902 when Bayliss and Starling discovered the 
chemical messenger that was later called the secretin hormone [4]. This was 
followed by the first human experiment treating T2DM with duodenal extract by 
Moore et al. in 1906 [5]. Although symptoms of diabetes appeared to improve 
with the duodenal extract treatment, it is important to note that quantification of its 
effects on plasma insulin was not possible until Yalow and Berson created the 
first insulin assay in 1961 [6]. Shortly after the development of this assay, two 
independent research groups headed by McIntyre and Elrick simultaneously 
communicated the discovery that oral administration of glucose induced a greater 
insulin response than IV infusion of glucose. This difference was called the 
incretin effect [7, 8].  
The incretin effect 
It is now known that there are two endogenous incretin hormones, glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). 
Both are released in response to ingestion of a mixed meal and affect insulin 
release. GIP was discovered and characterized in the 1970’s through isolation 
and characterization of gastrointestinal secretions and subsequent administration 
increases in insulin secretion [9]. In the 1980’s, GLP-1 was discovered because 
removal of GIP was not sufficient to eliminate the incretin effect [10], a finding 
that led to the identification of this second incretin peptide [11]. Additionally, in 
the 1980’s the incretin effect was shown to be reduced in patients with type two 
3 
diabetes (T2DM) [12]. It was later determined that GLP-1 has a stronger 
insulinotropic and glucose lowering effect during hyperglycemia than GIP in 
patients with T2DM [13]. Therefore, pharmacological treatments mimic GLP-1 
and target the GLP-1 receptor. Subsequent research developments showed that 
GLP-1 not only potentiates the release of insulin, but is responsible for up to 50% 
of post prandial insulin release [7, 8].  
Endogenous synthesis and degradation of GLP-1 
Endogenous synthesis of GLP-1 occurs in the L cells of the lower 
gastrointestinal tract. Within these cells, proglucagon is cleaved by convertase-1 
between amino acids 78-107 to release GLP-1. GLP-1 is also synthesized in and 
released from the brainstem [14], and tongue [15], which contribute to its effects 
as a neuroendocrine hormone locally, but not to its concentration in the 
circulation. The majority of GLP-1 in the circulation is in the GLP-1 (7-36) amide 
form and a minor amount as non-amidated GLP-1(6-36). These two forms of 
GLP-1 are equally active. Although basal levels of GLP-1 in the circulation 
average between 7-10pM, post-prandial levels peak 30 minutes after nutrient 
ingestion at 15-30pM [16-18].   
Immediately after release, GLP-1 is subject to degradation by dipeptidyl 
peptidase-4 (DPP4). DPP4 cleaves at the alanine at position two, and results in 
inactivation/ generation of the metabolite of GLP-1(9-36). DPP4 is highly 
expressed in the intestine and vascular endothelium and degradation of GLP-1 
occurs rapidly. The half-life is approximately two minutes in the human body. The 
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degradation product and remaining full length GLP-1 are cleared from circulation 
by the kidneys [19]. Although the half-life of GLP-1 in the circulation is brief, the 
duration of its release results in elevated circulating levels of GLP-1 for up to 
three hours after nutrient ingestion [17, 20]. Additionally, its actions are 
transduced through both neurological and endocrine means; therefore it may 
have a wide array of effects for various durations. 
Development of GLP-1 receptor agonists as a pharmacological treatment  
In 1992 GLP-1 infusion was shown to have a potent insulinotropic effect in 
non-diabetic and T2DM subjects. This was supported by studies with the GLP-1 
receptor antagonist, exendin (9-39), which inhibited the insulinotropic effect of 
GLP-1[21]. Additionally, a polymorphism in the gene for TCF7L2, which is known 
to be associated with T2DM, also affects the ability of GLP-1 to stimulate insulin 
secretion. It is possible that the lack of GLP-1 signaling in these patients results 
in the increased risk for T2DM in affected individuals [22]. Although it is known 
that patients with T2DM have a diminished incretin effect, whether this results 
from GLP-1 dysfunction or inhibition of its receptor is unknown. To circumvent 
the short half-life of endogenous GLP-1, pharmacological synthetic analogs 
resistant to the rapid DPP4 degradation were developed to treat the diminished 
incretin effect in T2DM patients.  
The first GLP-1 synthetic analog, exenatide, was derived from the saliva of 
heloderma horridum, a member of the bearded lizard family. Heloderma horridum 
survives on as little as one meal per year and maintains very low basal insulin 
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levels. When it does have the opportunity to eat, potentiation of the insulin 
response necessary to store nutrients post-prandially relies on a hormone in the 
saliva of the animal which is homologous in function, and partially in genetic 
sequence, to human GLP-1[23]. The heloderma horridum analog to GLP-1, 
however, is resistant to degradation by human DPP4. The GLP-1 synthetic 
analog synthesized from the heloderma horridum protein, Exenatide, has a 53% 
sequence homology with endogenous GLP-1 and a 2.4hr half-life in humans [24]. 
Studies with exenatide show that it corrects the diminished first and second 
phase insulin responses in T2DM patients [25]. In 2005 exenatide was cleared 
for use in patients with diabetes by the FDA.  
A second GLP-1 synthetic analog, liraglutide, was developed shortly after 
exenatide and was cleared for use by the FDA in 2010. It shares 97% sequence 
homology with human GLP-1, but has an additional C16 fatty acid side chain and 
a Lys to Arg amino acid substitution at position 34 [24]. These modifications 
inhibit its degradation by DPP4 and increased its half-life to 12hrs [24] allowing 
for a once daily injection for administration.  
Both liraglutide and exenatide have been shown to improve HbA1c, and 
cause moderate weight loss with a low risk for hypoglycemia [26]. Subsequent 
comparative analysis of the two synthetic analogs in the DURATION-6 trial 
indicated that liraglutide is more effective at improving glycemic control than 
exenatide, as measured by reduced HbA1c [27], but the reason why is unknown.   
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GLP-1 Receptor 
GLP-1 confers the majority of its effects through the widely expressed 
GLP-1 receptor (GLP-1R). First cloned in rats in 1992 [28], and then in humans 
in 1993 [23], GLP-1R is a 463 amino acid hepta-helical G protein-coupled 
receptor. Stimulation by GLP-1 induces rapid and reversible desensitization of 
the receptor in vivo [19]. GLP-1 receptors have been found in: alpha and beta 
cells of the pancreatic islets, brain, heart, kidney, GI tract and parietal cells of the 
stomach [29] and liver [30]. GLP-1R is also found in nerve terminals in the portal 
vein [31], portions of the vagus nerve in the GI tract, brain stem and arcuate 
nucleus [32], and in vascular endothelial cells [33].  
It is also possible that GLP-1 signals through additional receptors, as 
GLP-1R knock out mice retain measurable actions of infused 300pM GLP-1 on 
cardioprotective and vasodilatory effects [34]. Interestingly, the vascular effects 
of GLP-1 synthetic analog, exendin-4, infusion, were abolished by genetically 
knocking out the receptor. It should be noted however, that 300pM GLP-1 is 
roughly 10 times the concentration observed post-prandially in healthy 
individuals. Therefore it is possible that endogenous GLP-1 could cross react 
with an alternative receptor that it normally has a low affinity for. This would result 
in attribution of potential vascular effects that do not occur under in vivo GLP-1 
concentrations. Further investigation into potential dose effects of GLP-1 
warrants attention because roux-en-y-gastric bypass (RYGB) patients have been 
reported to reach post-prandial GLP-1 levels of 96pM, a three fold increase 
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above those observed in healthy normal weight controls [35]. These patients are 
also known to have decreased cardiovascular risk in long term follow up [36]. By 
utilizing a physiologically relevant range of GLP-1 concentration, it could be 
determined whether or not the GLP-1 receptor is necessary for all or some of the 
cardiovascular effects of GLP-1.  
Effect of GLP-1 on glucose homeostasis 
GLP-1 has a multitude of effects on the beta cell that result in the incretin 
effect described earlier. These include the following: increased glucose 
sensitivity, increased insulin synthesis and release, induction of beta cell 
proliferation, and decreased apoptosis and endoplasmic reticulum (ER) stress. 
GLP-1 improves beta cell glucose sensitivity by up-regulating the expression of 
glucose transporters and kinases, the molecular components of beta-cell glucose 
sensors. It is thought that these effects may account for the ability of GLP-1 to 
restore glucose response in previously resistant beta cells [37]. In conjunction 
with increasing the ability of the beta-cell to sense glucose, GLP-1 also up-
regulates insulin gene transcription, mRNA stability and biosynthesis [37]. 
Studies with GLP-1 and GLP-1R agonists have shown that these actions are 
through calcium (Ca2+) and cAMP/PKA dependent and independent, signaling 
[37].  
The effect of GLP-1 on glucose homeostasis is not limited to the beta cell. In 
1994 Hvidberg et al showed that GLP-1 infusion into healthy men inhibits 
glucagon secretion from alpha cells and improved post-prandial glucose levels 
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[38]. This effect was independent of hepatic glucose turnover or uptake [38]. 
Even more striking, treatment of type one diabetic patients with GLP-1 markedly 
inhibits glucagon release [39] further supporting a direct effect of GLP-1 on alpha 
cell glucagon release. The mechanism through which GLP-1 causes this effect 
on alpha cells is not known.  
In summary, GLP-1 affects pancreatic glucose homeostasis through effects 
on both the alpha and beta cells. This results in improved glucose sensitivity, 
insulin synthesis and secretion, promotion of proliferation/survival of the beta cell, 
and inhibition of glucagon release. It is likely that these effects are responsible for 
the improvements observed in T2DM patients on GLP-1 therapies and further 
implicate a diminished incretin effect in T2DM disease progression.  
Actions of GLP-1 in addition to glucose control  
In addition to being effective in improving glucose control in patients with 
T2DM, incretins improve many other aspects of metabolic disease as shown in 
Figure I.1. They include: protection from ischemic damage [40], effects on 
hepatic glucose uptake [41], reversal of  hepatic steatosis [42], inhibition of 
endogenous glucose production, and promotion of muscle glucose uptake [43], 
and cardioprotective and vasodilatory benefits [34]. Pertinent to the direction of 
this study, large scale retrospective trials of patients treated with GLP-1 synthetic 
analog therapies show significant improvements in macrovascular CVD risk [44-
49]. This differentiates GLP-1 synthetic analog therapies from other standard 
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Figure I.1: The biological actions of GLP-1 in addition to its effects on 
glucose regulation. This schema shows the variety of effects GLP-1 has been 
shown to have on different cells, tissues and organs. Many of these effects 
contribute to its beneficial effect on the pathogenesis of metabolic diseases.  
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therapies for intensive glucose control, which show minor to no improvement in 
risk. The intensive glucose control groups used in the UKPDS, ACCORD and 
VADT trials show little benefit in comparison to standard diabetes treatment on 
macrovascular CVD risk. Whether this CVD protective effect is due to 
improvements in the other aspects of metabolic disease depicted in Figure I.1 or 
direct effects on the vasculature was unclear at the start of this project.  
The inflammatory response of endothelial cells  
Vascular endothelial cells form the innermost part of the barrier between 
everything in the circulation and the body’s tissues. In this capacity, they are the 
first line of response and defense to signaling molecules and pathogens in the 
blood stream. Endothelial cell responses to stimuli range from changes in 
cell/barrier permeability, alterations in vasoconstriction and regulation of 
inflammation to attract immune response. In healthy vasculature, the 
inflammation induced immune response is important for protection against 
infection. In patients with obesity and/or diabetes however, elevated levels of pro-
inflammatory cytokines like TNFα or LPS [50, 51], result in a sustained 
inflammatory response. This sustained response results in endothelial 
dysfunction, which is independently linked to increased CVD risk [52]. For the 
purposes of this thesis, endothelial inflammation and dysfunction refer to the 
induction of expression of cellular adhesion molecules, mainly VCAM-1 and E-
selectin.   
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Endothelial dysfunction 
Endothelial dysfunction is widely reported as an initiating event in the 
pathogenesis of atherosclerotic cardiovascular disease (ASCVD). This is 
because it promotes monocyte adhesion through increased expression of cellular 
adhesion molecules. Cellular adhesion molecules include: vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-
selectin. As a group these transmembrane glycoproteins mediate cell-cell and 
cell-extracellular matrix interactions [53]. Endothelial VCAM-1 and ICAM-1 are 
members of the immunoglobulin superfamily and adhere to the integrins of 
leukocytes, recruiting them to the endothelium. E-selectin, a member of the 
Selectin family has been linked to leukocyte rolling, adhesion and transmigration 
across the endothelial cell layer [53]. Expression of adhesion molecule VCAM-1 
has been shown to increase binding of the types of leukocytes found in early 
human and experimental atheromas, such as the monocyte and T-lymphocyte 
[7]. In addition, VCAM-1 expression increases on endothelial cells overlying 
nascent atheroma [9] suggesting additional involvement over the course of the 
lesion development. These data support the view that endothelial dysfunction, 
leading to an increased expression of cellular adhesion molecules, contributes to 
early atherogenesis.  
Endothelial dysfunction also involves diminished availability of nitric oxide 
and an imbalance in the relative contribution of endothelium-derived relaxation 
and contraction factors [54]. The result is an imbalance, which leads to an 
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impairment of endothelium-dependent vasodilatation. This characteristic of 
endothelial dysfunction can be measured by flow mediated dilation (FMD) [55]. 
FMD, as measured by Doppler ultrasound, quantifies the vasodilatation that 
occurs after a temporary restriction of blood flow in a vessel, such as in the 
brachial artery [56]. FMD is reduced by inflammation and, conversely, treatments 
that suppress inflammation, improve FMD [57]. Reduced levels of nitric oxide 
(NO) also may contribute to VCAM-1 expression since NO inhibits cytokine 
induced endothelial activation and its expression of adhesion molecules and 
proinflammatory cytokines [58].  
Overall, endothelial dysfunction results in cellular adhesion molecule 
expression and diapedesis of monocytes. These monocytes engulf excess lipids, 
and are transformed into inflammatory foam cells that become cemented in the 
intimal space, as depicted in Figure I.2. This in turn generates a feed forward 
cycle of inflammation increased adhesion, diapedesis of monocytes, and 
formation of an atheroma [59].  In this project we focus on E-selectin, VCAM-1 
and ICAM-1 expression and the adhesion of monocytes to human aortic 
endothelial cells as a measurement of TNFα and LPS stimulated dysfunction. A 
goal of this project was to determine the effects of GLP-1 and the GLP-1 
synthetic analog liraglutide on inhibiting endothelial dysfunction stimulated by 
these cytokines. If GLP-1 and GLP-1 synthetic analogs confer a direct 
cardiovascular protective effect it could be through mediation of the inflammatory 
response to cytokines increased in diabetes/obesity. 
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Figure I.2: Initiation and progression of an atherosclerotic lesion. A: Healthy 
endothelial cells form a consistent barrier between the contents of the lumen and 
the intima/smooth muscle cells of the artery. B: When the endothelium becomes 
inflamed, cellular adhesion molecules are expressed to recruit monocytes. These 
monocytes diapedese through the endothelial cell layer. Within the intimal space 
monocytes differentiate into macrophages and consume oxidized LDL and other 
lipids. C: If the inflammatory stimulus is not cleared, monocyte recruitment 
escalates and an atherosclerotic lesion develops.  
A 
B 
C 
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Clarifying the cardiovascular benefits of GLP-1 and GLP-1 synthetic analog 
therapies 
Epidemiological studies:  
Multiple prospective epidemiological studies, currently collecting data on 
the possible cardiovascular effects of GLP-1 synthetic analog therapies, will 
culminate in the next 1-5 years. Currently, the only epidemiological study data 
available is retrospective analysis. Although it suggests a cardiovascular benefit, 
the data allows only for determination of correlation, not causation. One such 
example is the retrospective analysis of the LifeLink database. This study 
showed that patients treated with GLP-1 synthetic analog, exenatide (n=39,275), 
were 19% less likely to have a CVD event than patients treated with other 
glucose lowering agents (n=381,218).  
Additionally, they were less likely to experience CVD-related or all cause 
hospitalization [44]. Interestingly, patients on exenatide had more severe 
diabetes based on indicators of severity; use of combination therapy, metformin, 
or insulin. Additionally, these patients had higher baseline cardiovascular disease 
risk factors; hyperlipidemia, hypertension, ischemic heart disease, and use of 
therapies to correct these factors. Despite these factors, all three statistical 
methods used in this study: intention to treat- crude, propensity-score stratified, 
and propensity score weighted, all showed a significant reduction in 
cardiovascular disease events [44]. This is consistent with the possibility 
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that GLP-1 synthetic analog therapies add a significant CVD benefit above and 
beyond the therapies currently used to treat advanced diabetes and CVD risk 
factors.  
Data from the smaller prospective Liraglutide Effect and Action in Diabetes 
trial (LEAD trial) show that liraglutide treatment improves blood pressure and 
plasma markers of cardiovascular risk. LEAD found that liraglutide treatment 
(n=1304) results in reduced blood pressure, plasma triglycerides, plasminogen 
activator inhibitor-1 (PAI-1) and C-reactive protein (CRP) and increased brain 
natriuretic peptide (BNP) in comparison to placebo (n=503) [60].  
Once the results from the prospective trials currently going on are 
available it is likely that a more definitive statement about the attributes of GLP-1 
synthetic analog therapies will be possible.   
Clinical Studies and Trials  
Clinical trials with GLP-1 synthetic analog liraglutide have shown that it 
reduces markers of cardiovascular disease such as PAI-1 and CRP in the 
plasma of patients with T2DM [61]. It also improves plasma cardiovascular risk 
factors such as; reduced ADMA, E-selectin, PAI-1 and intact pro-insulin [48] in 
T2DM patients who were well controlled with metformin. Another GLP-1 synthetic 
analog, exenatide, BID for 16 weeks, improved flow-mediated dilation (FMD) in 
patients with T2DM already on metformin for glucose control [62]. Because 
patients who are well controlled on metformin have mild diabetes this supports 
the independence of the cardioprotective effect of GLP-1 synthetic analog 
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therapies from diabetes status. It also suggests that its effects are above and 
beyond those potentially conferred by common diabetes therapies, such as those 
shown with metformin [63]. Meta-analysis of 12 clinical trials for cardiovascular 
outcomes comparing exenatide BID (N = 2,316), placebo (n = 971) and insulin (n 
= 658) found that exenatide decreases cardiovascular risk [2]. Therefore, 
evidence from clinical trials indicates that GLP-1 synthetic analog therapy 
improves risk factors for cardiovascular disease and outcome measurements.  
 Clinical studies of GLP-1 receptor agonists indicate they have acute 
effects on cardiovascular disease markers. These acute effects have been 
performed by infusion of a single dose of GLP-1, exenatide, or liraglutide into 
diabetic and non-diabetic patients. Outcome measurements analyze endothelial 
dysfunction, an early event in ASCVD as well as plasma levels of inflammation 
markers. Infusion of GLP-1 improves flow mediated dilation in patients with 
coronary artery disease independent of diabetes status [33]. In a separate study, 
GLP-1 improved meal induced decreases in FMD and markers of hyperglycemia 
induced oxidative stress in both diabetic and non-diabetic subjects [49]. 
Additionally, particular to endothelium, clinical studies with synthetic analog 
exenatide show that a single dose improves peripheral artery tonometry, a 
measure of endothelial function, in patients with peripheral artery disease [48]. 
These studies suggest a direct acute effect of GLP-1 and GLP-1 synthetic 
analogs on cardiovascular disease risk through interaction with the endothelium. 
Overall these studies suggest that GLP-1 and its synthetic analogs have an 
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endothelial cell cardiovascular specific effect, which could account for the 
decrease in CVD risk observed in patients on synthetic analog therapies. The 
endothelial specific signaling mechanism behind these effects, however, is 
unclear.   
Mouse studies: In vivo 
Studies in atherosclerosis-prone ApoE deficient mice show that GLP-1 
infusion significantly reduced atherosclerotic plaque inflammation and size. This 
effect is ascribed, at least in part, to effects on macrophages [64, 65]. In support 
of this conclusion, incubation of macrophages with GLP-1 in vitro polarizes them 
towards an M2, or anti-inflammatory, phenotype [66]. While these studies are 
highly suggestive that GLP-1 directly affects the behavior of macrophages, which 
contribute significantly to atherogenesis, whether it also affects endothelium, has 
not been studied.  
In vivo studies of endothelial response to GLP-1 and the GLP-1 synthetic 
analog, liraglutide, have shown that it improves endothelial relaxation [67]. A 
measure considered to be similar to FMD in humans. In addition, liraglutide was 
shown to activate eNOS by phosphorylation, and inhibit ICAM-1 expression [67]. 
Both increasing eNOS and reducing ICAM-1 could affect macrophage 
recruitment, and reduce atherosclerotic plaque size and inflammation [64, 65]. 
Collectively, these studies strongly support the view that GLP-1 has a direct 
effect on the vasculature that exerts an anti-inflammatory effect on the 
endothelium.  
18 
Direct effect of GLP-1 and GLP-1 synthetic analog, liraglutide, on 
endothelial cell inflammation in vitro 
 Current GLP-1 and GLP-1 synthetic analog in vitro research makes 
several large assumptions in developing models potentially indicating the effects 
of these treatments on cardiovascular functions. These assumptions include the 
following: 1) transformed cell lines or human umbilical vein endothelial cells, 
neither of which are involved in atherogenesis in vivo, have the same responses 
as endothelial cells involved in atherosclerotic lesion formation 2) use of GLP-1 
synthetic analogs are interchangeable with GLP-1 and stimulate the same effects 
and pathways, 3) in vitro and in vivo effects are not dose dependent and 
supraphysiological levels reflect endogenous actions. With this in mind, the 
following section provides a brief overview of recently published studies focused 
on the potential cardiovascular benefits of GLP-1 and synthetic analogs 
exenatide and liraglutide.  
GLP-1: 
In vitro studies of human umbilical vein endothelial cells (HUVECs) reveal 
that physiological levels of GLP-1 (30pM) block advanced glycation end product 
(AGE) induction of reactive oxygen species (ROS) expression. Additionally, 
300pM GLP-1 blocks AGE induced vascular cell adhesion molecule-1 (VCAM-1) 
expression [68]. VCAM-1 is implicated in early atherogenesis because of its role 
in adherence of monocytes to the endothelial cell layer [68]. These monocytes 
then diapedese through the endothelial cell layer and secrete factors that 
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increase production of ROS, which damages surrounding cells and promotes 
atherogenesis [69]. If, as the previous data indicates, GLP-1 inhibits ROS and 
VCAM-1 expression, it may attenuate atherogenesis.  
Liraglutide: 
GLP-1 synthetic analog, liraglutide, has also been shown to have 
endothelial cell specific effects. Pre-treatment of HUVECs with liraglutide 
attenuates TNFα induced oxidative stress and activation of NF-kB [70]. Activation 
of NF- kB up-regulates the expression of cellular adhesion molecules VCAM-1, 
ICAM-1 and E-selectin. Inhibition of its activation has been previously shown to 
be associated with a reduction in VCAM-1 expression [71]. Liraglutide inhibits the 
activation of NF-κB by inhibiting phosphorylation and translocation from 
cytoplasm to the nucleus when induced by phorbol 12-myristate 13-acetate 
(PMA) [72]. Therefore, if liraglutide inhibits NF-κB activation, it could inhibit the 
induction of the expression of cell adhesion molecules VCAM-1, E-selectin and 
ICAM-1.  
Liraglutide also promotes eNOS expression and inhibits endothelin-1 (ET-
1) expression both at mRNA and protein levels in HUVECs [72]. Activation of 
eNOS increases nitric oxide (NO) synthesis [73], which scavenges superoxides 
[74], induces vasodilatation [75] and inhibits leukocyte adhesion [76]. Over-
expression of ET-1 in ApoE-/- mice results in lower levels of HDL, a two-fold 
increase in aortic atherosclerotic lesions and abdominal aortic aneurysms [77]. 
Additionally, in overweight and obese humans, a reduction in ET-1 levels has 
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been shown to result in an improvement in endothelial function [78], therefore 
potentially reducing cardiovascular disease risk.  
Therefore, liraglutide appears to reduce inflammation-stimulated 
expression of adhesion molecules and reduce risk factors for cardiovascular 
disease. The mechanism responsible for this effect, however, is unclear.  
Cellular signaling molecules in this thesis:  
A goal of this project was to determine the cellular signaling cascade 
responsible, or at least partially responsible, for the effects of GLP-1 and 
liraglutide on primary human aortic endothelial cells. The following sections 
provide a brief review of some of the cellular signaling molecules implicated in 
the cascade resulting in the anti-inflammatory effects of GLP-1/liraglutide.  
Calcium 
Calcium is an important second messenger in many cell types, including 
endothelial. It acts to link external stimuli with intracellular responses such as 
generation of NO, contraction/vascular tone, apoptosis, effects on mitochondria 
[79] and activation of kinases [80]. There are two sources of calcium from which 
flux can occur in the endothelial cell; mobilization of calcium from intracellular 
stores (endoplasmic or sarcoplasmic reticulum), and allowing entrance of 
extracellular calcium via store operated cation channels [81].  These 
mechanisms for calcium flux can be linked as release of intracellular calcium 
stores can stimulate the opening of transient receptor potential channels (TRPC), 
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an essential component of store operated cation channels, in the plasma 
membrane [82]. Recent data also suggests that there is an interaction between 
the depletion of intracellular calcium stores and the TRPC, in short, the depletion 
results in opening of TRPC [83]. 
CaMKKβ 
Calmodulin-dependent protein kinase kinase beta (CaMKKβ) is activated 
by influxes of calcium in the cell from intracellular sources, such as the 
endoplasmic reticulum, or from extracellular sources. CaMKKβ is also an 
upstream kinase for AMPK [84]. In human umbilical vein endothelial cells 
(HUVECs), thrombin activates AMPK through a pathway involving 
Ca2+/CaMKKβ [85]. CaMKKβ signaling in endothelial cells has also been 
implicated in regulation of actin cytoskeleton reorganization, voltage gated 
potassium channels, response to shear stress and redox- sensitive up-regulation 
of eNOS activity [86]. For the purpose of this study, we focus on the AMPK 
kinase activity of CaMKKβ.  
AMPK 
AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel 
and stress-sensing enzyme present in all mammalian cells. It is activated by 
three known AMPK kinases: LKB1, CAMKK-β and TAK1 [87, 88]. In addition, 
AMPK can be activated by increases in the AMP/ATP ratio resulting naturally 
from stress, exercise, and hypoxia, as well as pharmacologically by agents such 
22 
as metformin and thiazolidinediones [89-91]. Increases in the AMP/ATP ratio 
synergistically work with LKB1 to robustly activate AMPK [92]. Activation of 
AMPK in general decreases processes that consume ATP, such as: protein, 
triglyceride and cholesterol synthesis. It also causes an increase in processes 
that form ATP, such as: fatty acid oxidation and glycolysis [93, 94]. Previous 
studies have implicated AMPK as a target for treatments for metabolic disease 
by virtue of its involvement in lipid metabolism and cellular fuel regulation [95]. 
Additionally, targets of AMPK, such as eNOS are phosphorylated which 
modulates their activity. In the case of eNOS, phosphorylation results in 
activation and increased synthesis of nitric oxide (NO). Increased synthesis of 
NO has been shown to be atheroprotective [96] for its effects on vasodilatation 
and scavenging of superoxides [97]. We have previously demonstrated that 
activation of AMPK has anti-inflammatory effects against cytotoxicity induced by 
hyperglycemia and dyslipidemia [71] in endothelial cells. Additionally, some 
papers on the potential therapeutic benefits of GLP-1 in non-vascular tissue 
suggest activation of AMPK as a potential part of the mechanism involved in 
improving the respective metabolic damage [40, 42, 43, 98].  
Aims of this work: 
We have hypothesized that GLP-1 and GLP-1 synthetic analog liraglutide 
activate an endothelial cell specific mechanism that attenuates endothelial 
dysfunction through inhibition of inflammation. In keeping with this, the following 
specific aims were designed to test this hypothesis.  
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• Specific Aim #1: Determine if HAECs contain the necessary machinery to 
respond to GLP-1, mainly the GLP-1 receptor (GLP-1R) and the principle 
enzyme for GLP-1 degradation, dipeptidyl-peptidase-4 (DPP4).  
• Specific Aim #2: Determine if GLP-1/ liraglutide modulate the 
inflammatory response of HAECs to TNFα and LPS.  
• Specific Aim #3: Define the mechanism responsible for the anti-
inflammatory response of HAECs to GLP-1/liraglutide and determine if it is 
similar to mechanisms described in beta cells or hepatocytes.   
We addressed these aims with in vitro studies of primary human aortic 
endothelial cells exposed to inflammatory stimuli TNFα and LPS with or without 
addition of GLP-1 or liraglutide. We found that GLP-1 and liraglutide inhibit 
markers of endothelial dysfunction in response to TNFα and LPS, mainly by 
blocking transcription and translation of cellular adhesion molecules, and 
resulting monocyte adhesion. We also found that this effect was dependent on 
the activation of AMPK by influx of calcium activating CaMKKβ as shown in 
Figure I.3. This is a description of a novel mechanism through which GLP-1 and 
liraglutide confer an endothelial cell specific anti-inflammatory mechanism. In the 
following thesis we discuss the similarities and differences between GLP-1 and 
liraglutide, the potential implications of each on atherogenesis and the 
implications this data has on potential patient treatments. Additionally, we 
discuss how these results could shape additional areas of research interest and 
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current results on risk analysis for GLP-1 synthetic analogs already used to treat 
patients.   
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Figure I.3: Proposed cellular signaling cascade stimulated by liraglutide 
and GLP-1 which confers the anti-inflammatory effects. Key: → = leads to, 
┤= inhibits. 
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CHAPTER 1: Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits 
endothelial cell inflammation through a calcium and AMPK dependent 
mechanism 
 This chapter was submitted to PLoS One on December 4th, 2013 as: 
Krasner NM, Ido Y, Ruderman NB, Cacicedo JM. Glucagon-like peptide-1 (GLP-
1) analog liraglutide inhibits endothelial cell inflammation through a calcium and 
AMPK dependent mechanism.  
Abstract 
Liraglutide is a glucagon-like peptide-1 (GLP-1) synthetic analog used for 
the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, 
liraglutide potentiates the post-prandial release of insulin, inhibits glucagon 
release and increases satiety. Recent epidemiological studies and clinical trials 
have suggested that treatment with GLP-1 synthetic analogs may also diminish 
the risk of cardiovascular disease in diabetic patients. The mechanism 
responsible for this effect has yet to be determined; however, one possibility is 
that they might do so by a direct effect on vascular endothelium.  
Since low grade inflammation of the endothelium is an early event in the 
pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined 
the effects of liraglutide on inflammation in cultured human aortic endothelial cells 
(HAECs). Liraglutide reduced the inflammatory responses to TNFα and LPS 
stimulation, as evidenced by both reduced protein expression of the adhesion 
molecules VCAM-1 and E-selectin, and THP-1 monocyte adhesion. This was 
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found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ 
with known anti inflammatory actions in endothelial cells, including CaMKKβ, 
CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a 
CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the 
inhibition of TNFα and LPS-induced monocyte adhesion by liraglutide. Likewise, 
expression of an shRNA against AMPK nullified the anti-inflammatory effects of 
liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory 
effect on HAECs. They also demonstrate that this is due to its ability to increase 
intracellular Ca2+ and activate CAMKKβ, which in turn activates AMPK.  
Introduction 
GLP-1 is a peptide hormone secreted by the L cells of the large intestine 
in response to nutrient ingestion. It potentiates insulin secretion, blocks glucagon 
release and increases satiety [11, 99], but cannot be used directly as a therapy 
for Type 2 diabetes due to its short (2 minute) half life. On the other hand, 
pharmacological synthetic analogs have been developed with improved stability. 
One of these is liraglutide, in which the substitution of an Arg for Lys 34, and the 
addition of a C16 fatty acid at Lys 26 (using a γ-glutamic acid spacer) increases 
its half-life to 12 hours [100]. As does endogenous GLP-1, liraglutide potentiates 
insulin secretion [7, 8], improves HbA1c [101], and reduces post-prandial glucose 
levels [102] in patients with Type 2 diabetes. Its effects, however, are not limited 
to beta cells. Liraglutide also stimulates the satiety response [103], inhibits 
gastric emptying [103, 104], reduces intrahepatic lipid levels [105], induces 
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weight loss [101], and improves several markers of vascular function [106]. 
Interestingly, several large-scale retrospective trials have shown that GLP-1 
synthetic analog therapies improve biomarkers of cardiovascular disease (CVD) 
and diminish the incidence of CVD events [44-47]. Likewise, two smaller 
prospective studies have suggested that GLP-1 synthetic analogs diminish 
endothelial dysfunction [48, 49]. Although some of these improvements could be 
due to enhanced insulin secretion, and secondary changes in glucose and lipid 
metabolism, they could also reflect more direct effects of GLP-1 synthetic 
analogs on the endothelium, such as we investigate here.   
It is widely held that atherosclerotic cardiovascular disease (ASCVD) can 
begin with endothelial dysfunction caused by pro-inflammatory stimuli in the 
plasma. Patients with diabetes often have elevated plasma levels of TNFα and 
LPS [50, 51] both of which are associated with an increased risk of ASCVD [52]. 
TNFα and LPS increase the expression of adhesion molecules (VCAM-1, E-
selectin) on endothelial cells [107, 108] which in turn increase the adhesion of 
monocytes, the first step in the diapedesis of the latter into the intimal space 
where atherogenesis occurs [109]. Thus curtailing the ability of TNFα and LPS to 
induce the expression of VCAM and E-selectin would hypothetically decrease 
monocyte adhesion, and presumably atherogenesis.  
Liraglutide signals through the GLP-1 receptor (GLP-1R), which is 
expressed in many tissues including, pancreatic islets [110] and endothelium 
[33]. The cellular signaling mechanisms stimulated by GLP-1R agonists in 
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pancreatic β-cells are known [19], but whether GLP-1R agonists directly induce 
signaling in endothelial cells that could be cardioprotective is not clear. We 
demonstrate here that liraglutide exerts an anti-inflammatory effect on primary 
human aortic endothelial cells (HAECs) by causing a sequential increase in 
intracellular calcium, CaMKKβ activity, and activation of AMPK.  
Methods 
Cell Culture  
Human Aortic Endothelial Cells (HAECs) were purchased from Lonza and 
used between passages 5-7 (Lonza, Hopkinton, MA). Cells were cultured on BD 
primaria plates (BD, Franklin Lakes, NJ) in EGM-2 BulletKit media (Lonza, 
Hopkinton, MA) at 37.4° in a 5.5% CO 2 humidified incubator. Once cells became 
85-95% confluent, 3-4 days post-plating, they were serum starved overnight prior 
to various treatment. Trypsin was used to loosen cells for splitting as per Lonza’s 
instructions.  
Liraglutide 
American peptide (Sunnyvale, CA) cat #46-1-48A was solubilized as 
directed. 
Calcium Assay 
HAECs were cultured in EGM-2 on MatTek glass bottom culture dishes 
(P35G-0-14-C) and allowed to grow for three days post plating. Prior to the 
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addition of treatment, HAECs were serum starved overnight (1/8th concentration 
of serum of EGM-2), then treated with 2uM Fura-2 and 1/1000 dilution of pluronic 
acid for 30 minutes and washed with serum starve media for an additional 30 
minutes. Fura-2 is an indicator of intracellular calcium levels, when bound to 
calcium it excites at 340nM and when free at 380nM, therefore the ratio of the 
two indicates internal calcium levels when multiplied by the 225nM Kd. Pluronic 
acid increases permeability of the cell membrane to Fura-2 to assist its uptake. 
Individual dishes were placed in the ionoptix microscope and focused to show 
individual cells for tracking selection. Ion Optix software was used to track 
individual cells in designated zones. Background readings were taken for 
between 3-5 minutes to ensure a steady state, then the treatment, 100nM 
liraglutide, was added. Calcium levels continued to be tracked every 4 seconds 
over 30 minutes. 1uM Ionomycin, an ionophore which releases intracellular 
calcium was added to indicate the maximum intracellular calcium release. It 
should be noted that since HAECs are a primary cell line they differ both in size 
and in permeability to Fura-2. As a result, baseline differences between the 
individual cells is not relevant, rather changes in baseline intracellular calcium 
after to stimulation is the relevant measurement.  
Western Blot 
To determine both the cascade(s) involved in GLP-1 receptor stimulated 
signaling, and anti-inflammatory effects, protein quantity and phosphorylation 
were measured by western blot. To evaluate the cascade involved in liraglutide 
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signaling, HAECs were treated with 100nM Liraglutide over a time course 
spanning 25 minutes. Time points used were: 0, 1, 5, 10, 15, and 25 minutes 
after treatment addition. To evaluate the anti-inflammatory effects of Liraglutide 
cells were incubated with 100nM liraglutide for 1 hour prior to the addition of 
inflammatory stimulus- 10ng/mL TNFα or 2ug/mL LPS for an additional 3 hours. 
These experiments were independently repeated 6 times. After the treatment, 
plates were placed on ice, washed with cold PBS (3x) and 80-100uL of cell 
signaling lysis buffer was added to each well (1% Triton, 20mM Tris-HCl, 150mM 
NaCl, 1mM Na2 EDTA, 1mM EGTA, 25mM sodium pyrophosphate, 1mM β-
glycophosphate, 1mM Na3VO4, 1ug/ml leupeptin). Total protein was measure by 
Pierce BCA (Thermo Scientific). Between 10-18ug of protein was loaded per 
sample into a NuPage 4-12% Bis-Tris gel (Life technologies NP0336BOX). Gels 
were run in NuPage Mops SDS running buffer (NP0001) for approximately 1.5hrs 
at 150 volts. Proteins were transferred to Millipore immobilon-P membrane 
(IPVH00010) in NuPage transfer buffer (NP0006-1) at 25V for 1.5hrs and then 
blocked in 5% non-fat dry milk or blotto (5% fish gelatin, 3% BSA) for at least one 
hour at room temperature. Membranes were then incubated overnight with one of 
the following primary antibodies in 1/1,000 dilution: CaMKKβ from BD Bioscience 
(San Jose, CA), pCaMK1 (Thr177), GAPDH, VCAM-1, E-selectin from Santa 
Cruz Biotechnology (Santa Cruz, CA), pAMPK (Thr172), pACC (Ser79), peNOS 
(Ser1177), pCREB (Ser133) from Cell Signaling Technology (Danvers, MA), 
tAMPK from Epitomics (Burlingame, CA), β- Actin from Sigma (St. Louis, MO), 
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and tACC from Millipore (Temecula, CA). After washing the membrane (3x) in 
Tris- buffered saline (63mM Tris–HCl, 7.3mM NaCl) containing 0.1 % Tween 20 
(TBST), membrane was incubated for 1 hour with 1/10,000 diluted in TBST 
secondary antibody either anti-rabbit IgG horseradish peroxidase linked whole 
antibody from donkey (GE healthcare NA934V), or anti-mouse from sheep (GE 
healthcare NXA931). The membranes were then washed three times in TBST 
and antigen detection was performed using Thermo SuperSignal ECL, either 
West Pico (34080) or West Femto (34095) was used to visualize proteins. Band 
intensity was measure by Scion Image software and normalized to either 
GAPDH, or total protein for phosphorylation events.  
Monocyte Adhesion Assay 
Human aortic endothelial cells were grown in primaria (BD falcon) 24 well 
plates in EGM-2(Lonza) with 5mM glucose media. THP-1 monocytes were grown 
in 10mM glucose RPMI-1640 + 10% FBS, 1% penstrep and 1% glutamine in T-
75 flasks. Prior to addition of the monocytes to the HAECs, they were spun down 
at room temperature, 1000rpm for 5 minutes, and resuspended in PBS where 
they were dyed with 1uM CSFC (Mol. Probes/Invitrogen cat# C1157/in sterile 
DMSO Sigma cat#D2650) for 30min. They were then spun down again and 
resuspended in serum free RPMI-1640 for addition to the treated HAECs. 100uL 
of monocyte containing media was added to every well of the 24well plate except 
that for the dilution curve for quantification of monocyte number. Monocytes were 
allowed to adhere for 30min and then were washed away 3 times with room 
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temperature PBS. 100uL of EBM serum free media and 100uL of 2% triton-X 
lysis buffer were added to each well to lyse the monocytes. The samples were 
read at excitation of 485nm and emission of 520nm on an Infinite® M1000 from 
TECAN, which is a high-end multimode Microplate Reader with premium Quad4 
monochromators capable of monitoring UV, fluorescence and visible 
absorbencies.  
A standard curve and cell count was used to determine how many 
monocytes were present according to fluorescence level. The wells were then 
normalized to protein content as a marker of cell confluence/number. To visualize 
adhered monocytes, images were taken under phase contrast white light to 
visualize endothelial cells and excitation of 485nM and emission of 515nm for 
CFSC dye and then layered to show where the monocytes are adhered and their 
density. 
Short Hairpin RNA expressing Lentivirus 
The sequence TGAATTAAATCCACAGAAA was chosen as a target 
sequence for shRNA-mediated RNAi of human AMPKα1. The pSilencer 2.0 
vector (Ambion; Austin, TX) was used as the template for the human U6 
promoter that was cloned using the following PCR primers: forward primer (5-
GAATTC-CCCAGTGGAAAGACGC-3) and reverse primer (5-
GGTGTTTCGTCCTTTCCACAAGATATATAAAGGG-3). An shRNA expression 
cassette was created by tandem polymerase reaction of the U6 promoter 
template with one forward and two reverse primers as follows: forward, 5-
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CACCGCGCGC-CAAGGTCGGGCA-3, and reverse 1, 5-CTACACAAACT-
CCACCTGTTCAGCAATACGGTGTTTCGTCC-3 and reverse 2 5-
CCAAAAAAGTATTGCTGAACAGATG-GAACTACACAAACTC-3, which contains 
two GU pairing mutations in the sense strand. The resulting PCR product was 
inserted into pCR8-GW TOPO (Invitrogen) and then transferred by LR reaction to 
pDSL_hpUGIP shRNA lentivirus expression plasmid (ATCC). Three µg of the 
lentivirus plasmid was calcium phosphate-transfected along with 4.5µg of 
pLp1(gag-pol), 1µg of pLp2 (reverse), and 2µg of pLP/VSVG (VSVG) helper 
vectors into 293T cells grown in a six-well dish. Forty hours post- transfection, 
18mL of supernatant containing lentivirus was collected. The lentivirus was then 
purified using a kit (lentivirus production kit, ATCGbio.com, Vancouver, Canada). 
The HAECs were grown in 6 or 24-well plates as previous described and were 
infected by incubating overnight with virus (sh-scramble or shAMPK). The cells 
were visualized daily for GFP fluorescence (as the sh-lenti viruses co-express 
GFP) and then treated and harvested 3-4 days later. The virus infection 
efficiency was determined to by ~87% in our cells and caused an 83% drop in 
total AMPK protein levels in the sh-AMPK but not the sh-scramble infected cells. 
Use of the term knock down in this thesis refers to the process of the sh-AMPK 
infection preventing the synthesis of AMPK protein resulting in a decrease in total 
AMPK.  
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cAMP EIA  
After treatment, cells were harvested with 0.1N HCl. Protein levels were 
measured by BCA to ensure at least 1µg/µl and enzyme immunoassay 
performed as per manufacturer’s instruction to quantify cAMP levels with 
Cayman cAMP EIA kit (cat # 581001). Quantities were then normalized to 
sample protein level as determined by BCA.  
Statistics 
 Data are expressed as means +/- standard deviation. ANOVA with Tukey 
post tests and two tailed t test were used to analyze differences between groups 
of data as appropriate. p<0.05 was considered statistically significant.   
Results 
To increase the likelihood that the effects observed in these studies would 
be physiologically relevant primary human aortic endothelial cells (HAECs) were 
used. Additionally, the concentration of liraglutide utilized was 100nM, which is 
within the therapeutic range achieved in humans injected with 1.8mcg/day of the 
widely used brand of liraglutide, Victoza® [111].  
Liraglutide reduces protein expression of VCAM-1 and E-selectin in 
response to TNFα and LPS stimulation 
Patients with diabetes have increased plasma levels of TNFα and LPS 
[50, 51] both of which have been linked to increased cardiovascular disease risk 
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[52] and the induction of inflammatory responses in endothelial cells. The latter 
involves the expression of cellular adhesion molecules (CAMs) on the endothelial 
cell surface, which allows for firm adhesion of monocytes. To assess how 
liraglutide affects these events, HAECs were pre-incubated for 1 hr with 100nM 
liraglutide, and then co-incubated with either 10ng/mL TNFα or 2ug/mL LPS for 
3hrs to generate an inflammatory response. As shown in Fig 1.1, Liraglutide 
attenuated both TNFα and LPS stimulated expression of vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin.  
Liraglutide inhibits TNFα and LPS induced monocyte adhesion 
Monocytes are the largest of the cells classified as leukocytes and upon 
stimulation, they migrate to the vasculature, where they adhere, diapedese, and 
differentiate into mature macrophages [112]. Such macrophages are highly 
phagocytic, consume lipids and turn into inflammatory foam cells, a key event in 
the formation of atherosclerotic lesions [113]. THP-1 cells are a human 
monocytic cell line frequently used for monocyte to endothelial cell adhesion 
assays [114]. As shown in Figs 1.2A & C, liraglutide (100nM) attenuates TNFα 
(10ng/mL) and LPS (2µg/mL) stimulated THP-1 monocyte adhesion (see 
materials/methods). Representative pictures show fluorescent green (pseudo-
colored to black) labeled monocytes adhering to treated HAECs (Figure 2B, D). 
Thus, liraglutide decreases both the expression of adhesion molecules (Figure 
1.1) and the adhesion of monocytes to endothelial cells (Figure 1.2).  
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Effects of liraglutide on intracellular calcium and cAMP 
In pancreatic β-cells, GLP-1 signaling has been linked to its abilities to  
increase both cAMP and intracellular calcium [115, 116]. Calcium and cAMP are 
also involved in endothelial cell signaling [79, 81, 117]. Here we show that 
treatment with (100nM) liraglutide significantly increases intracellular calcium 
levels (Figure 1.3), and that 2500nM liraglutide (a supra-pharmacological 
concentration) causes an even greater increase in cell calcium (Figure 3D). 
Likewise, incubation with 100nM liraglutide caused a small, but statistically 
significant, increase in intracellular cAMP levels (Suppl. Figure 1.1), and a 
significantly greater increase when the cells are incubated with a supra-
pharmacological concentration of liraglutide (1000nM). Thus, liraglutide has 
concentration dependent effects on cell Ca2+ and to a somewhat lesser extent, 
cAMP.  
Liraglutide activates CaMKKβ leading to phosphorylation of AMPK 
(Thr172), CaMKI (Thr177), and other downstream targets  
To link the influx in calcium to the anti-inflammatory effects observed with 
liraglutide treatment, we examined other factors activated by increases in 
intracellular calcium that have been shown to also confer anti-inflammatory 
effects in endothelial cells. One of these is AMPK [118], an evolutionarily 
conserved fuel and stress-sensing enzyme that can be activated by calmodulin-
dependent protein kinase kinase-β (CAMKKβ) [87], which itself is activated by 
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increases in intracellular calcium, like those resulting from liraglutide treatment 
(Figure 3).  
Time course studies revealed that liraglutide stimulates the 
phosphorylation of AMPK resulting in the phosphorylation of its downstream 
targets pACC(ser79) and eNOS (ser1177) (Figure 1.4A, B, C). This suggests that 
calcium activated CaMKKβ could be acting as an AMPK kinase. In addition to 
AMPK, activated CaMKKβ phosphorylates and activates CaMK1 (Thr177) 
(Figure 4D). This is a key observation as in addition to PKA, CREB (ser133) can 
be phosphorylated by CaMK1 [119, 120], as seen in Figure 1.4D and E. Although 
such serine phosphorylation of CREB could also result from the small observed 
increase in cAMP, inhibition of CaMKKβ, and thereby CaMK1, with the CaMKKβ 
inhibitor STO-609 (further discussed below) also inhibited phosphorylation of 
CREB (Suppl. Figure 1.2), indicating that it is dependent on CaMKKβ activity. 
Moreover, although the time to peak activation seen in Figure 1.4 was consistent 
across different primary cell donors and cell passages, it occasionally ranged 
between 1-20 minutes for CaMK1 and AMPK with peaks for ACC, eNOS, and 
CREB phosphorylation occurring later.  
STO-609 inhibits CaMKKβ activity, blocking phosphorylation of AMPK and 
CaMKI and inhibiting their anti-inflammatory effects on monocyte adhesion  
To confirm that phosphorylation of AMPK and CaMK1 and their 
downstream targets are indeed downstream of CaMKKβ activation we 
preincubated HAECs with STO-609 before exposing them to liraglutide. STO-609 
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is a CaMKKα and CaMKKβ specific inhibitor that has been used in other studies 
to inhibit the phosphorylation of AMPK resulting from calcium fluxes [121]. Pre-
incubation with STO-609 effectively inhibited the phosphorylation of CaMK1 and 
AMPK (Figure 1.5A, B) and their downstream targets pCREB and peNOS (Suppl. 
Figure 2). In addition, STO-609 blocked the effects of liraglutide on TNFα and 
LPS induced monocyte adhesion (Figure 1.5E, F) demonstrating that this anti-
inflammatory benefit is also dependent on activation of CaMKKβ.  
ShRNA mediated knockdown of AMPK prevents the anti-inflammatory 
effect of liraglutide 
With the use of a lentivirus to express a shAMPK, we knocked down the 
expression of AMPK in HAECs. The latter was evident both microscopically, as 
the virus co-expressed a GFP tag allowing for visualization of infection (Suppl. 
Figure 1.3), and by significantly reduced (83%) AMPK protein levels (Suppl. 
Figure 1.3). Additionally, the lentivirus had no effect on the cellular density, as 
indicated by total cellular protein quantification (Suppl. Figure 1.3). The 
expression of shAMPK prevented liraglutide induced activation of AMPK (Figure 
1.6A) and its downstream target pACC (Figure 1.6B) as well as the anti-
inflammatory effects of liraglutide on monocyte adhesion (Figure 1.6C, D). These 
results indicate both that liraglutide activates AMPK, and that the latter is key to 
inhibiting monocyte adhesion, a putative early step in atherogenesis.  
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Discussion  
 It has been suggested by epidemiological [44-46, 122] and clinical studies 
 [33, 47, 48, 123, 124] that treatment with a GLP-1 receptor agonist, such as 
liraglutide, diminishes the risk of cardiovascular disease in patients with Type 2 
diabetes. The mechanism, however, by which it confers this benefit, is 
incompletely understood. The results of the present study suggest that liraglutide 
may act by inhibiting chronic inflammation in human aortic endothelial cells, an 
initiating event in atherogenesis. Thus we found that liraglutide diminishes both 
TNFα and LPS induced E-selectin and VCAM-1 expression, and the increase in 
monocyte adhesion that accompanies it. The results also demonstrate that 
liraglutide produces these effects by increasing cell Ca2+ and secondarily the 
activities of CAMKKβ and AMPK (Figure 1.7).  
 As recently reviewed, TNFα and LPS stimulated monocyte adhesion to 
endothelial cells are initiating events in the pathogenesis of atherosclerosis [125]. 
Therefore, our findings that liraglutide reduces the increased expression of 
VCAM-1 and E-selectin, and monocyte adhesion, caused by TNFα and LPS in 
HAECs (Figure 1.1A-D) could be highly relevant. Others have found that 
liraglutide inhibits high-glucose induced endoplasmic reticulum stress [126], and 
also TNFα induced markers of endothelial dysfunction such as PAI-1 [127], 
ICAM-1, and VCAM-1 in human umbilical vein endothelial cells (HUVECs) [70]. 
However, whether these effects could functionally affect endothelial cell 
monocyte interaction was not known. This is the first study demonstrating that 
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liraglutide directly diminishes monocyte adhesion to inflamed primary human 
aortic endothelial cells and find the mechanism by which this occurs. In healthy 
vasculature, diapedesis is important for immune protection against infection. In 
contrast, under atherogenic conditions, monocytes diapedese, engulf excessive 
lipids, become foam cells and adhere to the intimal space. This generates a feed 
forward cycle of inflammation, increasing adhesion and diapedesis of monocytes, 
and formation of an atheroma [59]. If, as shown here, liraglutide downregulates 
expression of adhesion molecules in endothelial cells, and subsequent to this, 
monocyte adhesion, it presumably is inhibiting atherogenesis.  
As already noted, the mechanism through which GLP-1R agonists, such 
as liraglutide, affect vascular endothelium has not been well studied. In 
pancreatic beta cells, they primarily signal through cAMP and calcium dependent 
mechanisms [115, 116]. We demonstrate here that stimulating HAECs with 
liraglutide (100nM) results in a significant increase in intracellular calcium (Figure 
1.3). To our knowledge, this is the first demonstration that liraglutide causes an 
increase in intracellular calcium in any cell type. The effects of liraglutide on 
intracellular calcium release were also shown to be dose dependent as high dose 
liraglutide (2500nM) treatment increased intracellular calcium to a greater extent 
(Figure 1.3D). Although liraglutide also increased cAMP levels, its effect at the 
concentration found in the circulation of patients (100nM) was small (Suppl. 
Figure 1.1).  
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The anti-inflammatory effects of liraglutide on endothelial cells observed in 
this study are similar to those observed previously by our lab following AMPK 
activation in HUVECs [71]. In the latter, E-selectin and VCAM1 were not 
measured; however, AMPK inhibited TNFα induced NF-κB activation [71], and 
decreased the expression of cellular adhesion molecules [51]. This is a key 
observation as cellular adhesion molecules generally require NF-κB for 
transcription. In this study we found that liraglutide activated AMPK and its 
substrate eNOS (Figure 1.4A, C). Activation of eNOS by AMPK increased nitric 
oxide (NO) synthesis [73], which scavenges superoxides [74], induces 
vasodilatation [75] and inhibits leukocyte adhesion [76]. Thus, the observed 
activation of AMPK by liraglutide (Figure 1.4A) suggests a potential mechanism 
for the anti-inflammatory effects previously discussed.  
There are two primary mechanisms for the activation of AMPK in 
endothelial cells, one through CaMKKβ [85] and the other LKB1 [128]. CaMKKβ 
is activated by an influx of calcium into the cytosol, an effect we have observed 
with liraglutide treatment, and which can occur independently of LKB1 [129]. In 
addition to activating AMPK, CaMKKβ phosphorylates and activates CaMKI at 
Thr 177 leading to its activation. Thus, it is noteworthy that liraglutide increased 
the phosphorylation of CREB at Ser 133, a known target of CaMKI [119]  (Figure 
1.4E, see also Figure 1.7). Although it is possible that the small observed 
increase in cAMP led to the activation of PKA, which also phosphorylates CREB 
at Ser 133, inhibition of CaMKKβ blocked the phosphorylation of CREB (Suppl. 
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Figure 1.3) suggesting that CaMK1 activity was most likely responsible for this 
effect.  
We discovered that activation of CaMKKβ by liraglutide is necessary for 
phosphorylation of AMPK and CaMK1 through use of STO-609, a CaMKKα and 
CaMKKβ specific inhibitor. STO-609 effectively blocked liraglutide stimulated 
phosphorylation of AMPK and CaMK1 (Figure 1.5A, B) and their targets, peNOS 
and pCREB (Suppl. Figure 1.3). Additionally, STO-609 blocked the anti-
inflammatory effects of liraglutide in that it prevented TNFα and LPS induced 
monocyte adhesion (Figure 1.5E, F). From this data we can conclude that 
liraglutide signals through CaMKKβ to activate CaMK1 and AMPK (Figure 1.7), 
and that this confers protection against TNFα and LPS induced monocyte 
adhesion.  
To determine whether or not the anti-inflammatory effects of liraglutide are 
also dependent on activation of AMPK, we knocked down AMPK expression with 
a lentivirus shAMPK. ShAMPK expression inhibited the ability of liraglutide to 
induce phosphorylation of AMPK at T172 (Figure 1.6A) and of the AMPK target 
ACC at S79 (Figure 1.6B). Importantly, it also prevented the ability of liraglutide 
to inhibit TNFα and LPS stimulated monocyte adhesion (Figure 1.6C, D). 
Therefore, the anti-inflammatory effects of liraglutide on human aortic endothelial 
cells are dependent on the activation of AMPK, as shown in Figure 1.7. 
 The results of the present study suggest that activation of CaMKKβ and 
AMPK by liraglutide could explain its reported cardiovascular benefits in patients 
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with Type 2 diabetes. Interestingly, cardiovascular benefits of GLP-1 synthetic 
analogs have also been found independent of diabetes. GLP-1 synthetic analog 
therapy improved global left ventricular (LV) function in patients with acute 
myocardial infarction and LV dysfunction after successful reperfusions [60], and 
ischemia in patients with coronary artery disease [61]. Unlike many other 
diabetes treatments, liraglutide does not create an added risk of hypoglycemia. 
Thus, it also could prove useful in non-diabetic patients at risk for atherosclerotic 
cardiovascular disease.   
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Figure 1.1: Liraglutide (100nM) prevents the inflammatory effects 
(increases in cellular adhesion molecules) induced by TNFα (10ng/mL) and 
LPS (2µg/mL) in HAECs. Liraglutide (100nM) prevents the inflammatory effects 
(increases in cellular adhesion molecules) induced by TNFα (10ng/mL) and LPS 
(2µg/mL) in HAECs. (A,B) HAECs were pre-incubated for 1hr with liraglutide and 
then co-incubated for 3hrs with TNFα (A,B) or LPS (C, D) to induce VCAM-1 and 
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E-selectin protein expression, (n=6). Anova with Tukey post tests, *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 1.2: Liraglutide (100 µM) prevents TNFα and LPS induced 
monocyte adhesion. Liraglutide (100 µM) prevents TNFα and LPS induced 
monocyte adhesion. HAECs were pre-incubated as described in Fig.1 with 
liraglutide for 1 hour and, then co-incubated with either 10ng/mL TNFα or 2ug/mL 
LPS for 3hrs. Fluorescent labeled THP-1 monocytes were then added and the 
incubation carried out for an additional 30 minutes. Liraglutide prevents (A) TNFα 
(n=6) and (C) LPS (n=8) stimulated monocyte adhesion. B,D: Representative 
Photomicrographs of HAECs treated as in (A and C) with adhered monocytes 
(visible as black dots) (10x magnification). *p<0.05, **p<0.01, ***p<0.001 
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Figure 1.3: Liraglutide (100nM) significantly increases intracellular 
calcium. Liraglutide (100nM) significantly increases intracellular calcium. Prior to 
the addition of liraglutide, HAECs were incubated with Fura-2, an indicator of 
intracellular calcium (See methods for details), n=21 for all results shown. A: 
HAECs were exposed to 100nM liraglutide where indicated by the arrow and 
tracked for 800 seconds. B: Bar graph shows intracellular calcium levels prior to 
100nM liraglutide treatment, (baseline is an average of 6 readings 236-256 
seconds) and at peak intracellular calcium subsequently achieved (628-648 
seconds) after its addition. C: Cells were tracked for 2000 seconds when 1uM 
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ionomycin was added to release all intracellular calcium from stores in the 
endoplasmic reticulum. D: Incubation with a supra-physiological level of 
liraglutide (2500nM) caused a greater increase in cell calcium, indicating a 
possible dose effect for this therapy. 
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Figure 1.4: Western blot analyses of calcium sensitive and anti-
inflammatory enzymes, 1-25 minutes following stimulation by 100nM 
liraglutide. Western blot analyses of calcium sensitive and anti-inflammatory 
enzymes, 1-25 minutes following stimulation by 100nM liraglutide. These graphs 
show the effects of liraglutide on the phosphorylation of pCaMK1 (Thr177), 
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pAMPK (Thr172), PACC (S79) peNOS (Ser1177) and pCREB (Ser133) (n=6) 
p<0.05, **p<0.01, ***p<0.001.  
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Figure 1.5: STO-609 inhibits liraglutide signaling and its effects on 
monocyte adhesion. STO-609 inhibits liraglutide signaling and its effects on 
monocyte adhesion. Cells were incubated with STO-609 for 30 minutes prior to 
addition of liraglutide: A: pAMPK (Thr172), (n=4) B: pCamK1 (Thr177), (n=4) C, 
D: TNFα and LPS stimulated monocyte adhesion (n=8). Liraglutide: 100nM, 
STO-609: 0.5ug/mL, TNFα: 10ng/mL, LPS: 2ug/mL. *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 1.6: shAMPK knocks down AMPK and inhibits the effects of 
liraglutide on AMPK and ACC phosphorylation, and monocyte adhesion. 
shAMPK knocks down AMPK and inhibits the effects of liraglutide on AMPK and 
ACC phosphorylation, and monocyte adhesion. A: AMPK phosphorylation 
(Thr172) B: ACC phosphorylation (Ser79). C,D: Infection of HAECs with 
shAMPK inhibited the liraglutide induced decrease in TNFα (10ng/mL) and LPS 
(2ug/mL ) stimulated monocyte adhesion (n=6). *p<0.05, **p<0.01, ***p<0.001. 
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Figure 1.7: Schema depicting the proposed mechanisms for the anti-
inflammatory effect of liraglutide on human aortic endothelial cells.  
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Supplemental Figure 1.1: Effect of 3 minute incubation with 100nM or 
1000nM liraglutide on cAMP levels in HAECs (n=10). *p<0.05, ***p<0.001.  
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Supplemental Figure 1.2: STO-609 inhibits the phosphorylation of 
targets of AMPK (eNOS), and CaMK1 (CREB). A) peNOS (Ser177), B) pCREB 
(Ser133). Liraglutide (100nM), STO-609 (0.5ug/mL) *p<0.05, **p<0.01, 
***p<0.001.  
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Supplemental Figure 1.3: shAMPK knocks down AMPK expression 
and inhibits the effects of liraglutide on monocyte adhesion. shAMPK 
knocks down AMPK expression. A: Quantification of western blot of total AMPK 
protein level normalized to GAPDH shows 82% reduction in tAMPK (n=6). D: 
Quantification of total cellular protein levels indicating virus does not affect cell 
density (n=6) .*p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 2: Glucagon-like peptide-1 (GLP-1) inhibits endothelial cell 
inflammation through a calcium and AMPK dependent mechanism 
 This will be submitted to PLoS One as: Krasner NM, Ido Y, Ruderman NB, 
Cacicedo JM. Glucagon-like peptide-1 (GLP-1) inhibits endothelial cell 
inflammation through a calcium and AMPK dependent mechanism.  
Abstract 
Glucagon-like peptide-1 (GLP-1) is a neuroendocrine incretin hormone, 
released upon nutrient ingestion from the intestinal L cells that potentiates insulin 
release [11, 99], slows gastric emptying [131], and induces satiety [20]. In 
addition to these responses, GLP-1 has several extrapancreatic actions in the 
brain, heart, liver, lungs and the vasculature (reviewed in [132]). Although the 
extent and mechanism responsible for many of these effects has been 
determined, the cardiovascular effects remain unclear. GLP-1 has been shown to 
induce arterial vasodilatation in experimental animals and humans [33, 49, 133]. 
This is intriguing because several of the molecular pathways responsible for 
vasodilatation, such as activation of endothelial nitric oxide synthase (eNOS) 
[134, 135] and AMP-activated protein kinase (AMPK) [136], also modulate 
vascular endothelium inflammation, an initiating event in atherosclerosis [125]. 
Interestingly, patients with diabetes and obesity have significantly reduced 
endogenous basal and post-prandial GLP-1 levels [17, 137] while having the 
highest risk for atherosclerotic cardiovascular disease (ASCVD). Whether 
endogenous GLP-1 modulates atherosclerosis in humans is not currently known, 
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however, one possibility is that it might do so by a direct effect on vascular 
endothelium. 
Since low-grade inflammation of the endothelium is an early event in the 
pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined 
the effects of GLP-1 on inflammation in cultured human aortic endothelial cells 
(HAECs). GLP-1 reduced the inflammatory responses to TNFα stimulation, as 
evidenced by reduced mRNA and protein expression of the adhesion molecules 
VCAM-1, ICAM-1 and E-selectin, and THP-1 monocyte adhesion. This was found 
to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with 
known anti inflammatory actions in endothelial cells, including CaMKKβ, CaMKI, 
AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK 
inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of 
TNFα induced monocyte adhesion by GLP-1. Likewise, expression of an shRNA 
against AMPK nullified the anti-inflammatory effects of GLP-1. The results 
indicate that GLP-1 exerts a strong anti-inflammatory effect on HAECs. They also 
demonstrate that this is due to its ability to increase intracellular Ca2+ and 
activate CAMKKβ, which in turn activates AMPK.  
Introduction 
Glucagon-like peptide-1 (GLP-1) is a neuroendocrine incretin hormone, 
released upon nutrient ingestion from the intestinal L cells that potentiates insulin 
release [11, 99], slows gastric emptying [131], and induces satiety [20]. In 
addition to these responses, GLP-1 has several extrapancreatic actions in the 
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brain, heart, liver, lungs and the vasculature (reviewed in [132]). Although the 
extent and mechanism responsible for many of these effects has been 
determined, the cardiovascular effects remain unclear. Interestingly, patients with 
diabetes and obesity have significantly reduced endogenous basal and post-
prandial GLP-1 levels [17, 137] while having the highest risk for atherosclerotic 
cardiovascular disease (ASCVD). Whether reduced endogenous GLP-1 and 
increased risk of ASCVD are linked is unknown. However, it has been shown that 
roux-en-y-gastric bypass (RYGB) patients have an immediate and dramatic 
increase in circulating GLP-1 levels; which is sustained for at least 6 years [138], 
and may contribute to the significant reduction in cardiovascular events observed 
14.7 years post surgery [36]. Although increased GLP-1 is one of many 
cardioprotective changes resulting from RYGB, studies in atherosclerosis-prone 
ApoE deficient mice show that GLP-1 significantly reduced atherosclerotic plaque 
inflammation and size [64, 65]. While these studies are highly suggestive that 
GLP-1 directly affects the role of macrophages in atherogenesis, whether it also 
affects endothelium, is unclear. In this study we examined whether endogenous 
GLP-1 exerts a direct anti-inflammatory effect on endothelial cell (EC) 
inflammation, modulates EC-monocyte interaction, and the mechanism 
responsible.  
GLP-1 has previously been shown to induce arterial vasodilatation in 
experimental animals and humans [33, 49, 133]. This is intriguing because 
several of the molecular pathways responsible for vasodilatation, such as 
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activation of endothelial nitric oxide synthase (eNOS) [134, 135] and AMP-
activated protein kinase (AMPK) [136], also modulate vascular endothelium 
inflammation. Endothelial cell inflammation is an initiating event in 
atherosclerosis [125], which is critical as atherosclerotic cardiovascular disease 
(ASCVD) is the leading cause of death in patients with diabetes and obesity 
[139]. Whether endogenous GLP-1 modulates atherosclerosis in humans is not 
currently known, but the following evidence suggests it may play a significant role 
in vascular inflammation. 
Endothelial cell inflammation results from stimulation by cytokines like 
TNFα and LPS, which are elevated and linked to ASCVD in patient with diabetes 
[50, 51]. Stimulation with TNFα/LPS results in the expression of cellular adhesion 
molecules (CAMs), such as VCAM-1 or E-selectin, and promotes adhesion of 
monocytes to the endothelial cell layer.  Monocyte adhesion is the first step in 
their diapedesis into the intimal space, and initiation of atherogenesis [109]. 
Therefore, inhibiting TNFα and LPS induced monocyte adhesion to the 
endothelial cell layer would conceivably suppress the development of the 
atherosclerotic lesion. We demonstrate here that GLP-1 exerts a direct anti-
inflammatory effect on primary human aortic endothelial cells (HAECs) by 
causing a sequential increase in intracellular calcium, CaMKKβ activity, and 
activation of AMPK, leading to inhibition of monocyte adhesion.  
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To our knowledge this is the first proposal of a mechanism through which 
GLP-1 attenuates the inflammatory response of endothelial cells to TNFα and 
LPS, and that the mechanism is dependent on calcium signaling and AMPK.  
Methods 
Cell Culture 
Human Aortic Endothelial Cells (HAECs) were purchased from Lonza and 
used between passages 5-7 (Lonza, Hopkinton, MA). Cells were cultured on BD 
primaria plates (BD, Franklin Lakes, NJ) in EGM-2 BulletKit media (Lonza, 
Hopkinton, MA) at 37.4° in a 5.5% CO 2 humidified incubator. Once cells became 
85-95% confluent, 3-4 days post-plating, they were serum starved overnight prior 
to various treatment. Trypsin was used to loosen cells for splitting as per Lonza’s 
instructions.  
GLP-1 
American peptide (Sunnyvale, CA) cat #46-1-12A solubilized as directed. 
Calcium Assay 
HAECs were cultured in EGM-2 on MatTek glass bottom culture dishes 
(P35G-0-14-C) and allowed to grow for three days post plating. Prior to the 
addition of treatment, HAECs were serum starved overnight, then treated with 
2uM Fura-2 and 1/1000 dilution of pluronic acid for 30 minutes and washed with 
serum starve media for an additional 30 minutes. Fura-2 is an indicator of 
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intracellular calcium levels, when bound to calcium it excites at 340nM and when 
free at 380nM, therefore the ratio of the two indicates internal calcium levels 
when multiplied by the 225nM Kd. Pluronic acid increases permeability of the cell 
membrane to Fura-2 to assist its uptake. Individual dishes were placed in the 
ionoptix microscope and focused to show individual cells for tracking selection. 
Ion Optix software was used to track individual cells in designated zones. 
Background readings were taken for between 3-5 minutes to ensure a steady 
state, then the treatment, 10-30pM GLP-1, was added. Calcium levels continued 
to be tracked every 4 seconds over 30 minutes. 1uM Ionomycin, an ionophore 
which releases intracellular calcium was added to indicate the maximum 
intracellular calcium release. It should be noted that since HAECs are a primary 
cell line they differ both in size and in permeability to Fura-2. As a result, baseline 
differences between the individual cells is not relevant, rather changes in 
baseline intracellular calcium after to stimulation is the relevant measurement.  
RT-PCR: 
HAECs were cultured in EGM-2 on 6-well primaria plates until 85-95% 
confluent and were serum starved overnight prior to treatment. Total RNA from 
cells was extracted with Triazol. Density of RNA was read by nanodrop, and 3ug 
of mRNA was used for reverse transcription with random decamers (Ambion 
5722G), dNTP (Promega U151B), 5x First Strand Buffer, 0.1M DTT and MMLV 
(Invitrogen 28025-013) to make cDNA.  Resulting cDNA was then diluted 10 fold 
and mixed 1:1 with Takara (Mountain View, CA) SYBR* Premix Ex Taq* DNA 
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Polymerse with primers. RT-PCR was performed in Cepheid 25uL tubes in a 
Cepheid Smart Cycler system (Hamburg, PA) with melting point analysis. PCR 
products were run on an agarose gel to confirm product size. The following 
primers were used to detect mRNA: VCAM 5’-ACACACAGGTGGGACACAAA-3’ 
(forward), 5’-GGTGCTGCAAGTCAATGAGA-3’ (reverse); E-selectin 5’-
CTCTGACAGAAGAA-3’ (forward), 5’-ACTTGAGTCCACTG-3’ (reverse); 
Cyclophilin A 5’-AGGGTTCCTGCTTTCACAGA-3’ (forward), 5’-
CTTGGCAGTGCAGATGAAAA-3’ (reverse), ICAM-1 5’-
CAGGGAATATGCCCAAGCTA-3’(forward), 5’-TGAACCATGATTGCACCACT-3’ 
(reverse).  
Western Blot 
To determine both the cascade(s) involved in GLP-1 receptor stimulated 
signaling, and anti-inflammatory effects, protein quantity and phosphorylation 
were measured by western blot. To evaluate the cascade involved in liraglutide 
signaling, HAECs were treated with 100nM Liraglutide over a time course 
spanning 25 minutes. Time points used were: 0, 1, 5, 10, 15, and 25 minutes 
after treatment addition. To evaluate the anti-inflammatory effects of Liraglutide 
cells were incubated with 100nM liraglutide for 1 hour prior to the addition of 
inflammatory stimulus- 10ng/mL TNFα or 2ug/mL LPS for an additional 3 hours. 
These experiments were independently repeated 6 times. After the treatment, 
plates were placed on ice, washed with cold PBS (3x) and 80-100uL of cell 
signaling lysis buffer was added to each well (1% Triton, 20mM Tris-HCl, 150mM 
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NaCl, 1mM Na2 EDTA, 1mM EGTA, 25mM sodium pyrophosphate, 1mM β-
glycophosphate, 1mM Na3VO4, 1ug/ml leupeptin). Total protein was measure by 
Pierce BCA (Thermo Scientific). Between 10-18ug of protein was loaded per 
sample into a NuPage 4-12% Bis-Tris gel (Life technologies NP0336BOX). Gels 
were run in NuPage Mops SDS running buffer (NP0001) for approximately 1.5hrs 
at 150 volts. Proteins were transferred to Millipore immobilon-P membrane 
(IPVH00010) in NuPage transfer buffer (NP0006-1) at 25V for 1.5hrs and then 
blocked in 5% non-fat dry milk or blotto (5% fish gelatin, 3% BSA) for at least one 
hour at room temperature. Membranes were then incubated overnight with one of 
the following primary antibodies in 1/1,000 dilution: CaMKKβ from BD Bioscience 
(San Jose, CA), pCaMK1 (Thr177), GAPDH, VCAM-1, E-selectin from Santa 
Cruz Biotechnology (Santa Cruz, CA), pAMPK (Thr172), pACC (Ser79), peNOS 
(Ser1177), pCREB (Ser133) from Cell Signaling Technology (Danvers, MA), 
tAMPK from Epitomics (Burlingame, CA), β- Actin from Sigma (St. Louis, MO), 
and tACC from Millipore (Temecula, CA). After washing the membrane (3x) in 
Tris- buffered saline (63mM Tris–HCl, 7.3mM NaCl) containing 0.1 % Tween 20 
(TBST), membrane was incubated for 1 hour with 1/10,000 diluted in TBST 
secondary antibody either anti-rabbit IgG horseradish peroxidase linked whole 
antibody from donkey (GE healthcare NA934V), or anti-mouse from sheep (GE 
healthcare NXA931). The membranes were then washed three times in TBST 
and antigen detection was performed using Thermo SuperSignal ECL, either 
West Pico (34080) or West Femto (34095) was used to visualize proteins. Band 
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intensity was measure by Scion Image software and normalized to either 
GAPDH, or total protein for phosphorylation events.  
Monocyte Adhesion Assay 
Human aortic endothelial cells were grown in primaria (BD falcon) 24 well 
plates in EGM-2(Lonza) with 5mM glucose media. THP-1 monocytes were grown 
in 10mM glucose RPMI-1640 + 10% FBS, 1% penstrep and 1% glutamine in T-
75 flasks. Prior to addition of the monocytes to the HAECs, they were spun down 
at room temperature, 1000rpm for 5 minutes, and resuspended in PBS where 
they were dyed with 1uM CSFC (Mol. Probes/Invitrogen cat# C1157/in sterile 
DMSO Sigma cat#D2650) for 30min. They were then spun down again and 
resuspended in serum free RPMI-1640 for addition to the treated HAECs. 100uL 
of monocyte containing media was added to every well of the 24well plate except 
that for the dilution curve for quantification of monocyte number. Monocytes were 
allowed to adhere for 30min and then were washed away 3 times with room 
temperature PBS. 100uL of EBM serum free media and 100uL of 2% triton-X 
lysis buffer were added to each well to lyse the monocytes. The samples were 
read at excitation of 485nm and emission of 520nm on an Infinite® M1000 from 
TECAN, which is a high-end multimode Microplate Reader with premium Quad4 
monochromators capable of monitoring UV, fluorescence and visible 
absorbencies.  
A standard curve and cell count was used to determine how many 
monocytes were present according to fluorescence level. The wells were then 
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normalized to protein content as a marker of cell confluence/number. To visualize 
adhered monocytes, images were taken under phase contrast white light to 
visualize endothelial cells and excitation of 485nM and emission of 515nm for 
CFSC dye and then layered to show where the monocytes are adhered and their 
density. 
Short Hairpin RNA expressing Lentivirus 
The sequence TGAATTAAATCCACAGAAA was chosen as a target 
sequence for shRNA-mediated RNAi of human AMPKα1. The pSilencer 2.0 
vector (Ambion; Austin, TX) was used as the template for the human U6 
promoter that was cloned using the following PCR primers: forward primer (5-
GAATTC-CCCAGTGGAAAGACGC-3) and reverse primer (5-
GGTGTTTCGTCCTTTCCACAAGATATATAAAGGG-3). An shRNA expression 
cassette was created by tandem polymerase reaction of the U6 promoter 
template with one forward and two reverse primers as follows: forward, 5-
CACCGCGCGC-CAAGGTCGGGCA-3, and reverse 1, 5-CTACACAAACT-
CCACCTGTTCAGCAATACGGTGTTTCGTCC-3 and reverse 2 5-
CCAAAAAAGTATTGCTGAACAGATG-GAACTACACAAACTC-3, which contains 
two GU pairing mutations in the sense strand. The resulting PCR product was 
inserted into pCR8-GW TOPO (Invitrogen) and then transferred by LR reaction to 
pDSL_hpUGIP shRNA lentivirus expression plasmid (ATCC). Three µg of the 
lentivirus plasmid was calcium phosphate-transfected along with 4.5µg of 
pLp1(gag-pol), 1µg of pLp2 (reverse), and 2µg of pLP/VSVG (VSVG) helper 
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vectors into 293T cells grown in a six-well dish. Forty hours post- transfection, 
18mL of supernatant containing lentivirus was collected. The lentivirus was then 
purified using a kit (lentivirus production kit, ATCGbio.com, Vancouver, Canada). 
The HAECs were grown in 6 or 24-well plates as previous described and were 
infected by incubating overnight with virus (sh-scramble or shAMPK). The cells 
were visualized daily for GFP fluorescence (as the sh-lenti viruses co-express 
GFP) and then treated and harvested 3-4 days later. The virus infection 
efficiency was determined to by ~87% in our cells and caused an 83% drop in 
total AMPK protein levels in the sh-AMPK but not the sh-scramble infected cells. 
Use of the term knock down in this thesis refers to the process of the sh-AMPK 
infection preventing the synthesis of AMPK protein resulting in a decrease in total 
AMPK.  
cAMP EIA  
After treatment, cells were harvested with 0.1N HCl. Protein levels were 
measured by BCA to ensure at least 1µg/µl and enzyme immunoassay 
performed as per manufacturer’s instruction to quantify cAMP levels with 
Cayman cAMP EIA kit (cat # 581001). Quantities were then normalized to 
sample protein level as determined by BCA.  
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Statistics 
 Data are expressed as means +/- standard deviation. ANOVA with Tukey 
post tests and two tailed t test were used to analyze differences between groups 
of data as appropriate. p<0.05 was considered statistically significant.   
Results 
Primary human aortic endothelial cells (HAECs) were used for all of the 
following experiments, as these cells would be susceptible to atherogenesis in 
vivo. The concentration of glucagon-like peptide-one (GLP-1) used, 30pM, is well 
within the documented levels reached post-prandially in the plasma of healthy 
individuals [16]. GLP-1 is 29 amino acid long protein which is post-
transcriptionally cleaved between amino acids 78-107 from the proglucagon gene 
within the L cells of the small intestine [29]. The majority is also amidated on the 
C-terminus prior to release, but this appears to have no effect on function.  
GLP-1 inhibits inflammatory stimuli induced ICAM-1, VCAM-1 and E-
selectin mRNA and protein expression  
TNFα and LPS are inflammatory factors that induce endothelial 
dysfunction, as shown by expression of cellular adhesion molecules (CAMs), and 
have been linked to increasing cardiovascular disease risk [52]. In the following 
studies HAECs were pre-incubated for 1hr with 30pM GLP-1, and then co-
incubated with 10ng/mL TNFα for 3hrs to generate an inflammatory response. 
RT-PCR for mRNA indicated that GLP-1 inhibited initiation of transcription of 
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ICAM-1, VCAM-1, and E-selectin by TNFα (Figure 2.1A-C). Similar results were 
obtained with use of lipopolysaccharide (LPS) stimuli (Supplemental Figure 2.1A-
C). Western blot for protein expression showed that pre-incubation with GLP-1 
also attenuated TNFα stimulated ICAM-1, VCAM-1 and E-selectin expression 
(Figure 2.1D-F). This indicates that endogenous GLP-1 inhibits TNFα and LPS 
stimulated endothelial dysfunction in expression of cellular adhesion molecules, a 
key mediator of endothelial cell and leukocyte adhesion.  
GLP-1 diminishes inflammation induced monocyte adhesion 
In ASCVD, inflammation triggers the production of CAMs on endothelial 
cells. These CAMs promote adhesion of monocytes, a type of leukocyte, which 
upon stimulation, migrate to the vasculature, adhere to the endothelium and 
diapedese into the intimal space of the artery [112]. Within the artery, monocytes 
differentiate into mature macrophages which are highly phagocytic, consume 
lipids, and turn into inflammatory foam cells, forming of the atherosclerotic lesion 
[113]. Thus, adhesion of monocytes to the endothelium is a key regulator in the 
process of atherogenesis. THP-1 cells are a human monocytic cell line frequently 
used for monocyte to endothelial cell adhesion assays [114]. Monocyte 
adherence assays (see materials/methods) showed that pre-incubation with 
GLP-1 (30pM) attenuated TNFα (10ng/mL) stimulated THP-1 monocyte adhesion 
(Figure 2.2A). Additionally, the same effect was found with LPS (2µg/mL) 
stimulated monocyte adhesion (Suppl. Figure 2.2A). Representative pictures 
show fluorescent green (pseudo-colored to black) labeled monocytes adhering to 
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treated HAECs (Figure 2.2B, Suppl. Figure 2.2B). Thus, GLP-1 decreases both 
the expression of adhesion molecules (Figure 2.1) and the adhesion of 
monocytes to endothelial cells (Figure 2.2).  
GLP-1 activates AMPK (Thr172)  
 GLP-1 has been shown to confer anti-inflammatory effects on 
hepatocytes, in models of NASH, through separate cAMP and AMPK dependent 
mechanisms [140]. AMPK is an evolutionarily conserved fuel and stress-sensing 
enzyme which, when activated, has anti-inflammatory effects in the vasculature 
[118]. Although, we found no effect of GLP-1 on cAMP levels (Supple. Figure 
2.3), we did find activation of AMPK. Time courses revealed that GLP-1 
stimulated the phosphorylation of AMPK, and phosphorylation of its targets 
pACC(ser79) and eNOS (ser1177) (Figure 2.3A-C). 
GLP-1 induced activation of AMPK is calcium dependent 
GLP-1 signaling has been shown to be dependent on increasing cAMP 
and intracellular calcium in beta cells [115, 116]. Both calcium and cAMP are 
also involved in many mechanisms of endothelial cells signaling [79, 81, 117]. 
We did not observe any change in cAMP, but we did find that GLP-1 significantly 
increased intracellular calcium levels (Figure 2.4). To our knowledge, this is the 
first report indicating GLP-1 increases calcium in endothelial cells.  
In determining the mechanism for activation of AMPK, it has been shown 
that increased intracellular calcium can activate calcium/calmodulin-dependent 
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protein kinase kinase-β (CaMKKβ), an AMPK kinase, resulting in 
phosphorylation. Phosphorylation of AMPK was shown to be dependent on 
CaMKKβ activity as pre-incubation with STO-609, a CaMKK specific inhibitor, 
abolished this effect. Additionally, STO-609 abolished phosphorylation of AMPK 
target, peNOS Ser1177.  
GLP-1 activates CaMKKβ leading to phosphorylation CaMKI (Thr177) and 
downstream targets  
Activated CaMKKβ has also been shown to phosphorylate CaMK1, which 
we also found with GLP-1 treatment. Phosphorylation of CaMKI target, CREB 
(ser133) (Figure 2.3E) further supported this cascade as depicted in Figure 2.7 
Pre-incubation with STO-609 inhibited the phosphorylation of CaMK1 indicating 
its dependence on activated CaMKKβ. The time courses shown in Figure 3 are 
representative of what was found many times, however the time to peak 
response varied between 1-20 minutes depending on cell donor and passage.   
STO-609 inhibits anti-inflammatory effect of GLP-1 on monocyte adhesion.  
We show here that, GLP-1 stimulates a mechanism involving an increase 
in intracellular calcium leading to CaMKKβ activation, phosphorylation of AMPK 
and CaMK1 and their downstream targets eNOS and CREB (Figure 2.5A,B,D). 
Additionally, STO-609 inhibited the effects of GLP-1 on TNFα induced monocyte 
adhesion (Figure 2.5C), demonstrating that this anti-inflammatory benefit is 
dependent on GLP-1 activation of CaMKKβ.  
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ShRNA mediated knockdown of AMPK prevents the anti-inflammatory 
effect of GLP-1 
Lentivirus expression of shAMPK was used to knock down AMPK in 
HAECs, as shown by reduced AMPK protein levels (Supple Figure 2.4C) and 
visualization of viral GFP tag by microscope (Supple Figure 2.4A,B). The 
lentivirus had no effect on the cellular density, as indicated by the total cellular 
protein quantification (Supple. Figure 2.4C). Knockdown of AMPK prevented 
activation of AMPK (Figure 2.6A) and its target pACC (Figure 2.6B) by GLP-1. 
Additionally, the effects of GLP-1 on TNFα and LPS stimulated monocyte 
adhesion (Figure 2.6C,D) was inhibited by AMPK knockdown. Thus, this 
indicates that the anti-inflammatory effects of GLP-1 are dependent on CaMKKβ 
induced activation of AMPK.  
Discussion:  
 Diabetes and obesity dramatically raise cardiovascular disease risk due, in 
part, to elevated levels of inflammation and dyslipidemia. These factors, 
however, may not be solely responsible for the increased risk in patients with 
these diseases. In addition to elevated inflammation and dyslipidemia, patients 
with diabetes and/or obesity have reduced levels of GLP-1. Recent murine and 
human studies, and data from this study, suggest that endogenous GLP-1 
improves markers of cardiovascular disease. Additionally, retrospective 
epidemiological studies of patients treated with GLP-1 receptor agonists indicate 
reduced cardiovascular risk [44-46, 122]. The precise mechanism for this risk 
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reduction, however, is unclear. Determining the role of endogenous GLP-1 on 
CVD risk could result in improved therapy protocols to curtail development of 
CVD. Here we show that GLP-1 has both an endothelial cell specific anti-
inflammatory effect and the mechanism through which this effect is conferred.  
In clinical trial GLP-1 infusion improved left ventricular ejection fraction 
[124], meal induced decrease in flow mediated dilation (FMD), and markers of 
hyperglycemia induced oxidative stress [49]. As an indicator of vascular 
endothelial function, improvement in FMD suggests a direct effect of GLP-1 on 
the endothelium. Dysregulated inflammation of the endothelium is widely 
reported as an initiating event in the pathogenesis of atherosclerotic 
cardiovascular disease (ASCVD). Endothelial cell dysfunction occurs in response 
to inflammatory stimuli like TNFα and LPS which have been independently linked 
to increased risk for CVD (citation). Patients with diabetes/obesity have elevated 
levels of these stimuli [50, 51] in circulation. Endothelial cell dysfunction initiates 
ASCVD by promoting monocyte adhesion and diapedesis. In healthy 
vasculature, diapedesis is important for immune protection against infection. In 
contrast, under atherogenic conditions, monocytes diapedese, engulf excessive 
lipids, and become inflammatory foam cells cemented in the intimal space. This 
generates a feed forward cycle of inflammation increasing adhesion and 
diapedesis of monocytes, and formation of an atheroma [59]. Our results 
demonstrate that GLP-1 inhibits inflammation in human aortic endothelial cells 
(HAECs), an initiating event in atherosclerotic cardiovascular disease (ASCVD). 
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We found that GLP-1 diminishes both TNFα and LPS induced E-selectin and 
VCAM-1 expression, and the increase in monocyte adhesion that accompanies it 
which could be highly relevant in preventing the pathogenesis of atherosclerosis 
[125]. 
This study shows that GLP-1 confers a distinct anti-inflammatory effect, 
inhibition of CAMs and monocyte adhesion, on the endothelium. The anti-
inflammatory effect of GLP-1 has also been demonstrated in models of 
nonalcoholic steatohepatitis (NASH). GLP-1 was shown to protect against NASH 
through effects on inflammation and beta oxidation of lipids in hepatocytes [140, 
141]. These effects were shown to be the result of stimulation of cAMP and PI3K, 
and independently, AMPK [140]. We show here that GLP-1 activates AMPK by 
phosphorylation of Thr 172 in HAECs (Figure 2.3A). Additionally, substrates of 
AMPK, endothelial nitric oxide synthase (eNOS, Ser1177) and acetyl CoA 
carboxylase (ACC, Ser79) in HAECs (Figure 2.3B, C) are phosphorylated. Unlike 
the mechanism of GLP-1 signaling in hepatocytes, we found no effect on cAMP 
levels (Supple. Figure 2.3). Our lab has previously shown that activation of 
AMPK inhibited TNFα induced NF-κB activation [71], and decreased the 
expression of cellular adhesion molecules [51]. This is a key observation, as 
cellular adhesion molecules generally require NF-κB for transcription. 
Additionally, activation of eNOS by AMPK increases nitric oxide (NO) synthesis 
[73], which scavenges superoxides [74], induces vasodilatation [75] and inhibits 
leukocyte adhesion [76]. Thus, the observed activation of AMPK by GLP-1 
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(Figure 2.3A) suggests two potential mechanisms for the anti-inflammatory 
effects; inhibition of NF-kB, and activation of eNOS. 
To determine the mechanism through which GLP-1 induces activation of 
AMPK, we looked for potential upstream signaling. In pancreatic beta cells, GLP-
1 signals, in part, through calcium dependent mechanisms [115, 116]. 
Additionally, calcium influx has previously been sown to activate AMPK through 
calcium induced activation of CaMKKβ, an AMPK kinase. We demonstrate here 
that stimulating HAECs with GLP-1 (30pM) results in a significant increase in 
intracellular calcium (Figure 2.3). To our knowledge, this is the first implication of 
calcium as a potential signaling mechanism for GLP-1 in endothelial cells. In 
addition to phosphorylation and activation of AMPK, activated CaMKKβ 
phosphorylates CaMK1 at Thr177. GLP-1 treatment also increased phospho-
CaMK1 Thr177 (Figure 2.3D) and phosphorylation of CREB at serine 133, a 
known target of pCaMKI [119] (Figure 2.3E).  
STO-609, a CaMKK specific inhibitor, blocked the phosphorylation of both 
AMPK and CaMK1 and their targets (Figure 2.5A,B), confirming their activation 
by CaMKKβ. Additionally, pre-treatment with STO-609 inhibited the effects of 
GLP-1 on TNFα stimulated monocyte adhesion (Figure 2.5C). This indicates that 
activation of CaMKKβ by GLP-1 results in activation of AMPK, CaMK1 and 
inhibition of TNFα and LPS stimulated monocyte adhesion.  
To determine the extent to which the anti-inflammatory effects of GLP-1 
are dependent on activation of AMPK, we knocked down AMPK expression with 
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a shAMPK lentivirus. ShAMPK expression inhibited the ability of GLP-1 to induce 
phosphorylation of AMPK (Figure 2.6A) and AMPK target ACC (Figure 2.6B). 
Importantly, the shAMPK prevented the anti-inflammatory effects of GLP-1 
against TNFα stimulated monocyte adhesion (Figure 2.6C). This data indicates 
that the functional anti-inflammatory effects of GLP-1 on aortic endothelial cells 
are dependent on activation of AMPK and provides evidence towards a potential 
cascade for the anti-inflammatory effects of GLP-1 on endothelial cells (Figure 
2.7). 
The data presented here indicates a direct anti-inflammatory action of 
GLP-1 on the endothelium and that this action is dependent on activation of 
AMPK. To our knowledge, this is the first time this mechanism has been shown 
in endothelial cells. This is important because patients with diabetes/obesity have 
drastically reduced levels of endogenous GLP-1. Interestingly, obese patients 
that undergo roux-en-y-gastric (RYGB) bypass have dramatically elevated levels 
immediately after surgery [142] and significantly reduced cardiovascular disease 
risk in comparison to controls [143, 144]. Determining the effect that GLP-1 may 
be having in these patients is critical to developing successful therapeutic 
interventions for patients with diabetes/obesity before and after surgery. Our data 
shows that the effects of GLP-1 on the endothelium are independent of diabetes 
status, and may confer significant CVD risk reduction through decreased 
inflammation. This supports improving the efficacy of treatments which increase 
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endogenous GLP-1 in patients with increased ASCVD risk, especially those with 
reduced endogenous levels, like those with obesity or diabetes.  
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Figure 2.1: GLP-1 (30pM) prevents TNFα (10ng/mL) induced increase 
in cellular adhesion molecules transcription and translation in HAECs. 
HAECs were pre-incubated for 1hr with GLP-1 (30pM) and then co-incubated for 
3hrs with TNFα (10ng/mL) to induce VCAM-1, ICAM-1 and E-selectin mRNA (A-
C) (n=3) or protein (D-F) expression (n=6). nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001.  
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Figure 2.2: GLP-1 (30pM) prevents TNFα induced monocyte 
adhesion. HAECs were pre-incubated with GLP-1 for 1 hour and, then co-
incubated with 10ng/mL TNFα for 3hrs. CFSE fluorescent labeled THP-1 
monocytes were then added and the incubation carried out for an additional 30 
minutes. GLP-1 prevents (A) TNFα stimulated monocyte adhesion (n=6) B) 
Representative Photomicrographs of HAECs treated as in (A) with adhered 
monocytes (visible as black dots ) (10x magnification). nsp>0.05, *p<0.05, 
**p<0.01, ***p<0.001. 
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Figure 2.3: Representative western blot analyses of calcium sensitive 
and anti-inflammatory enzymes, 1-25 minutes following stimulation by 
30pM GLP-1. These graphs show the effects of GLP-1 on the phosphorylation of 
pCaMK1 (Thr177), pAMPK (Thr172), PACC (S79) peNOS (Ser1177) and pCREB 
(Ser133).  
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Figure 2.4: GLP-1 (30pM) significantly increases intracellular 
calcium. Prior to the addition of GLP-1, HAECs were incubated with Fura-2, an 
indicator of intracellular calcium (See methods for details). A) HAECs were 
exposed to 30pM GLP-1 where indicated by the bar and tracked for 1800 
seconds (n=9). B) Bar graph shows intracellular calcium levels prior to 30pM 
GLP-1 treatment, (12 measurements between 240-284secs), to peak stimulation 
(12 measurements between 1380-1424 seconds) (n=9). nsp>0.05, *p<0.05, 
**p<0.01, ***p<0.001 
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Figure 2.5: STO-609 inhibits GLP-1 signaling and its effects on 
monocyte adhesion. Cells were incubated with STO-609 for 30 minutes prior to 
addition of GLP-1: A) pAMPK (Thr172), B) pCamK1 (Thr177). C) TNFα 
stimulated monocyte adhesion (n=8). ), D) peNOS (ser11177). GLP-1: 30pM, 
STO-609: 0.5ug/mL, TNFα: 10ng/mL. nsp>0.05, *p<0.05, **p<0.01, ***p<0.001.  
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Figure 2.6: shAMPK knocks down AMPK protein level and inhibits 
the effects of GLP-1 on AMPK and ACC phosphorylation, and monocyte 
adhesion. A) AMPK phosphorylation (Thr172). B) ACC phosphorylation (Ser79). 
C) Infection of HAECs with shAMPK inhibited the GLP-1 induced decrease in 
TNFα (10ng/mL) stimulated monocyte adhesion (n=6). D) Total AMPK protein of 
control and virus treated cells (n=6). nsp>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.7: Schema depicting the proposed mechanisms for the anti-
inflammatory effect of GLP-1 on human aortic endothelial cells.  
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Supplemental Figure 2.1: GLP-1 (30pM) prevents LPS (2µg/mL) 
induced increase in cellular adhesion molecules expression in HAECs. 
HAECs were pre-incubated for 1hr with GLP-1 (30pM) and then co-incubated for 
3hrs with LPS (2ug/mL) to induce (A) VCAM-1(n=3), (B) ICAM-1 (n=3) and (C) 
E-selectin (n=3) mRNA expression. nsp>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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Supplemental Figure 2.2: GLP-1 (30pM) prevents LPS (2µg/mL) 
induced monocyte adhesion. HAECs were pre-incubated with GLP-1 for 1 hour 
and, then co-incubated with for 3hrs. Fluorescent labeled THP-1 monocytes were 
then added and the incubation carried out for an additional 30 minutes. A) GLP-1 
prevents LPS stimulated monocyte adhesion (n=6). B) Representative 
Photomicrographs of HAECs treated as in (A) with adhered monocytes (visible 
as black dots) (10x magnification). nsp>0.05, *p<0.05, **p<0.01, ***p<0.001 
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Supplemental Figure 2.3: Effect of a 3 minute incubation with 30pM or 
300pM GLP-1 on cAMP levels in HAECs (n=10). nsp>0.05, *p<0.05, **p<0.01, 
***p<0.001 
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Supplemental Figure 2.4: shAMPK infection and expression does not 
reduce cell density. A, B) 20x Micrographs of HAECs under bright field (A) and 
fluorescence to show the presence of GFP indicating positive virus infection (B). 
C) Quantification of total cellular protein levels indicating virus does not affect cell 
density (n=6). nsp>0.05, *p<0.05, **p<0.01, ***p<0.001.  
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CHAPTER 3: HAECs contain the necessary machinery to respond to GLP-1, 
mainly the GLP-1 receptor (GLP-1R) and principle degradative enzyme, 
dipeptidyl-peptidase-4 (DPP4) 
The following studies were performed as part of this thesis project, but not 
included in the previous papers for publication 
GLP-1 Receptor: 
It is now accepted that the GLP-1 receptor (GLP-1R) is expressed and 
active in human endothelial cells. This conclusion, however, was not 
substantiated when this project began. Therefore, to ensure that human aortic 
endothelial cells (HAECs) possess the necessary machinery to transduce signals 
from GLP-1, or synthetic analogs, we determined if the receptor was present. We 
showed that HAECs express the GLP-1R through RT-PCR with the expected 
product size (Figure 3.1A) and western blots for GLP-1R protein using antibody 
(Abcam Ab39072) (Figure 3.1C). This indicated that the receptor is transcribed 
and translated. Its activity, however, was still unclear. Since these initial findings, 
our data, and publications by others, confirm the presence and activity of the 
GLP-1R on human endothelial cells.  
It is known that the GLP-1R has a 20 amino acid N-terminal signal peptide 
sequence which contains hydrophobic residues and is critical for synthesis and 
processing of the integral membrane protein. After removal of this sequence, the 
protein undergoes N-linked glycosylation in the lumen of the endoplasmic 
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reticulum (ER). Although cleavage of the signal peptide is not necessary for 
synthesis of the GLP-1R, it is necessary for processing and trafficking to the 
plasma membrane [145]. Our western blots of HAECs suggested that there are 
two proteins around ~50kD size for the GLP-1 receptor, one more prominent 
band at 53kD, and one lighter band at 49kD (Figure 3.1C). Whether or not these 
bands reflect membrane bound or intracellular forms of the receptor has yet to be 
determined.  
In an attempt to maximize cellular response to GLP-1, we tried to over-
express the receptor by lentivirus infection. Infection of the HAECs was 
confirmed through use of the V5 antibody (Figure 3.1C, E) indicating 
incorporation of the viral genome into the host HAEC. The expression level of the 
GLP-1R, however, did not appear to increase at either molecular weight (Figure 
3.1B, C, D). Interestingly, according to the V5 epitope, the receptor made from 
the virus construct was only in the lower molecular weight band (Figure 3.1C). 
There are many potential explanations for the lack of increased GLP-1R 
expression despite the lentivirus appearing to have worked. For example, it is 
possible that the receptor expression is limited by negative feedback and 
excessive amounts are degraded.  
In further studies, fractionation of HAECs to separate the plasma 
membrane and cytosol could clarify if the observed molecular weight difference 
indicates the location of the GLP-1R. Additionally, removal the N-linked 
glycosylations and/or removal of the 20 amino acid signaling sequence could 
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clarify what is responsible for the size difference between these two bands. The 
principle interest of this study was to determine the downstream effects of GLP-1 
and synthetic analog liraglutide on HAEC inflammation/dysfunction. Therefore, 
because the attempt to over-express the receptor failed, these studies were 
discontinued.   
GLP-1R expression in mouse aortic endothelium  
Immunohistochemistry (IHC) of samples taken from C57BL6 mice allowed 
us to see that expression of the GLP-1R was also present in mouse aortic 
endothelium (Figure 3.2). Further studies on GLP-1R expression variability with 
age, diabetes or obesity status/duration would contribute significantly to the 
current body of knowledge on the receptor. Although studies have been recently 
published on the receptor dependent and independent effects of GLP-1, and 
GLP-1 synthetic analogs, on mouse and human endothelium, the receptor 
expression levels have not been analyzed.  
GLP-1R expression in adipose tissue  
There is limited data available on the effect of GLP-1 on adipocytes, a 
study by Challa et al showed that 10nM GLP-1 increased pre-adipocyte 
differentiation of primary adipocytes. Additionally, results from murine fibroblast 
cell line 3T3-L1, which can be differentiated into adipocytes, indicate that this 
effect is dependent on the GLP-1R [146]. In our study, GLP-1R expression was 
found in the inguinal fat pads of db/db and db/+ mice (Figure 3A) but not clearly 
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on the adipocytes themselves. There was, however, a noticeable difference 
between GLP-1R staining of adipose tissue between the diabetic and non-
diabetic mice (see chapter 3 methods). Specifically, the tissue from the db/db 
mice showed intense GLP-1R localization within the crown like structures. Crown 
like structures are formed around dying adipocytes and contain monocytes and 
macrophages [147]. As can be seen in Figure 3.3A, fluorescent macrophage 
staining (performed by Julia Xu) and IHC for the GLP-1R overlap in location. 
Supporting this, the GLP-1 has been shown to be expressed on circulating 
monocytes and macrophages [148].  
The presence of the GLP-1R in the crown-like structures, likely on 
macrophages could be relevant in adipose tissue inflammation. Monocytes and 
macrophages are known to be important in the inflammatory state of adipose 
tissue [149, 150]. In our studies using THP-1 cells (a leukemia monocyte cell 
line) we have shown that treating the monocytes alone with GLP-1 
downregulated their adhesive capacity in response to TNFα stimulated HAECs 
(Figure 3.3B). Other studies have shown that GLP-1 polarizes human monocyte 
derived macrophages to the anti-inflammatory M2 phenotype [66]. Additionally, in 
human monocytes, GLP-1 synthetic analog exendin-4 reduced the expression of 
CD11b, a protein involved in diapedesis of monocytes, an initiating event in 
atherogenesis [151]. Therefore, GLP-1 could have an anti-inflammatory effect on 
the monocytes localized within crown-like structures. Stimulating these 
monocytes and macrophages with GLP-1 may reduce adipose tissue 
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inflammation, a well documented pathology of metabolic disease and diabetes 
[147, 152]. A potential line of further investigation of the effects of GLP-1 on 
macrophages would be to show whether GLP-1 affects adipose tissue 
inflammation. To this end, a future direction of research based on this data would 
be to treat db/db mice with GLP-1, or a GLP-1 receptor agonist, to test its effects 
on development of inflammation in adipose tissue.  
Di-peptidyl peptidase-4 (DPP4) expression  
DPP4 is a highly expressed serine protease enzyme which cleaves the 
Xaa-Ala or Xaa-Pro from the N-terminus of peptides. It is anchored to the plasma 
membrane of endothelia in almost all organs, and solubilized in plasma and 
cerebrospinal fluid [153]. Additionally, DPP4 is the main degradative enzyme of 
GLP-1. Inhibition of DPP4 has been shown to increase circulating levels of 
endogenous GLP-1 leading to its development as a pharmaceutical treatment.  
We showed here that HAECs express DPP4 by RT-PCR (Figure 3.4A) 
and western blot (Figure 3.4B). DPP4 expression was also shown on the 
endothelium of C57B6 mice by immunohistochemistry (Figure 3.4C). Therefore, 
not only does the vascular endothelium express the GLP-1 receptor, it expresses 
the capacity to degrade GLP-1.  
Additionally, we found that incubation of HAECs with high glucose (25mM) 
resulted in increased activity of DPP4 which resulted in increased degradation of 
GLP-1 (Figure 3.5). Using gly-pro-p-nitroanilide (GPN), a chemical that changes 
absorbance at 405nM upon cleavage by DPP4, we showed that incubation with 
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high glucose resulted in increased degradation of GPN (Figure 3.5A). This 
indicates increased activity of DPP4. We then tested whether this resulted in an 
increase in GLP-1 degradation. Using an N-terminally flag-tag labeled GLP-1 (the 
site where DPP4 cleaves GLP-1) we were able to quantify the amount of 
cleavage products after co-incubation of the labeled GLP-1 with HAECs. This 
showed that high glucose increased the degradation of GLP-1, and that this 
process could be inhibited by aprotinin, a serine protease inhibitor (as noted 
before, DPP4 is a serine protease) (Figure 3.5B). It is known that people with 
diabetes have lower basal and post-prandial circulating levels of GLP-1. 
Currently, it is unknown if increased degradation or decreased secretion is 
responsible for why these patients have decreased levels of GLP-1 [154]. This 
effect of hyperglycemia on DPP4 activity may be at least partially responsible for 
the reduced circulating levels of GLP-1 in diabetics. Further studies of the 
presence and effect of GLP-1R agonists in adipose tissue and activity of DPP4 
would contribute significantly to the field of incretin research.  
In addition to DPP4 expression on the aortic endothelium, we showed by 
immunohistochemistry that DPP4 is expressed in the islets of the pancreas of 
C57B6 mice (Figure 3.4D). Although the type of cell where the expression was 
shown was not determined, the location and morphology of the cell excludes it 
from being a vascular endothelial cell. In addition to this expression, it is likely 
that the vascular endothelial cells lining the vascular of the pancreas also 
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express DPP4. This indicates that another known target of GLP-1 activity also 
possess the capacity to degrade it.  
It is possible that the capacity to degrade GLP-1 is a means to control its 
signaling at the level of the target cells and tissues. However, although inhibition 
of DPP4 confers anti-inflammatory and vasculoprotective effects [133], and 
DPP4 levels are elevated in obesity [148], whether inflammation up-regulates the 
expression or activity of DPP4 has yet to be determined. This increased 
expression may act to reduce the ability of GLP-1 to polarize monocytes towards 
an anti-inflammatory M2 state as it has been previously shown to do [66]. 
Interestingly in this study, diabetes status of the obese subjects did not affect 
DPP4 levels, only obesity. It would be interesting to follow up on this with IHC for 
DPP4 of the pancreas from db/db diabetic and db/+ non-diabetic mice to see if 
there is a difference in expression between these two groups.  
Methods (additional to those described in the previous papers for 
publication) 
Lentivirus infection of GLP-1 receptor construct:  
GLP-1 receptor (human gene GLP-1R) expressing lentivirus plasmid was 
created by LR recombination reaction of pLent6 lentivirus plasmid (Invitrogen, 
Grand Island, NY) and pENTR223 vector carrying GLP-1R (BC111843). 
Lentivirus was made by using Lentivirus production kit (ATCGbio life technology 
Vancouver, Canada ) as following instruction. 
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Db/db and Db/+ mice: 
Db/db mice are homozygous for a defect in the leptin receptor which leads 
to a defect in the satiety response, among other issues. This culminates in 
development of diabetes and obesity in these mice. Db/+ mice retain an active 
form of the receptor and maintain normal phenotypic response. Db/db and db/+ 
littermate mice used for this study were purchased at 9 weeks of age. At 13 
weeks, db/db became diabetic, while db/+ remained non-diabetic. Diabetes was 
confirmed by weekly blood tests and was maintained for 1 month prior to organ 
harvest. Organs were processed by pathology at BMC and were stained by IHC 
for the GLP-1R using an antibody from Santa Cruz (Santa Cruz, CA, SC-66911) 
by us. 
Immunohistochemistry:  
Dissected aortas were formalin-fixed, paraffin embedded, cut in 5-µm 
slices, and mounted on slides by the Experimental Pathology Laboratory 
Services Core at Boston University School of Medicine. For 
immunohistochemistry (IHC) analyses, the slides were deparafinized and 
hydrated through washes that took the slides from xylene, 100% ethanol, 95% 
ethanol, 85% ethanol, 75% ethanol, 50% ethanol, and then water. Antigens were 
unmasked by flash boiling the slides in 10mM Tris (pH 10) and then cooling for 
30 min. Native peroxides were quenched with 3% H2O2 (10 min). The reagents 
from the UltraTech HRP Streptavidin-Biotin Universal Detection System 
(Beckman Coulter, Fullerton, CA) were used to block, amplify, and detect the 
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primary antibodies according to manufacturer's guidelines. All primary antibodies, 
at a concentration of 1:50 to 1:100, were incubated overnight at 4°C in a 
humidified chamber. Detection was based on secondary biotinylated antibody, 
followed by the addition of streptavidin-HRP ABC complex and 3,3′-
diaminobenzidine. Post-detection, the slides were dehydrated and Permount 
(Fisher) was used to seal the cover slip. For negative controls, the primary 
antibody was omitted. 
Gly-pro-p-nitroanilide (GPN) studies:  
 Gly-pro-p-nitroanilide was purchased from Sigma Aldrich (St. Louis, MO) 
cat # G0513 and solubilized in 0.1 M Tris-HCl, pH 7.4. Final concentration of 
GPN in plated media was 0.6mM. After treatment and addition of GPN, plates of 
samples were read for absorbance at 405nM on an Infinite® M1000 from 
TECAN. The TECAN is a high-end multimode Microplate Reader with premium 
Quad4 monochromators capable of monitoring UV, fluorescence and visible 
absorbencies. Readings were taken even 5 minutes for 4 hours to track the 
change in absorbance.  
Fluorescein Isothiocyanate (FITC)- tagged GLP-1: 
 100nM GLP-1 labeled on the N-terminus with FITC (FL-tag-GLP1) was 
incubated with HAECs. Active DPP4 cleaves the last two N-terminal amino acids 
from GLP-1, therefore removing the FITC tag. Exclusion chromatography of the 
media containing full length labeled GLP-1 and the products of DPP4 induced 
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cleavage; the GLP-1 metabolite and the FITC tag attached to the N-terminal two 
amino acids was performed. This allowed for separation of the cleaved tags from 
the full length and other portion of the degraded GLP-1 pieces. A standard curve 
allowed for quantification of the cleavage product and therefore analysis of the 
activity of DPP4 on cleaving GLP-1. This was done with and without serine 
protease and DPP4 inhibitor, aprotinin. Prevention of the increase degradation of 
GLP-1 by aprotinin indicates that increased activity of a serine protease is 
responsible for the increased degradation of GLP-1. This information combined 
with the GPN studies shows that high glucose leads to increased activity of 
DPP4 and increased degradation of GLP-1 by a serine protease, most likely, 
DPP4 (Figure 3.5A,B).  
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Figure 3.1: Lenti-virus overexpression of the GLP-1 receptor. A) Gel 
of RT-PCR products for GLP-1R primers, anticipated replication sequence size~ 
156bp. B) 53kD GLP-1R levels in cells were no different between virus infected 
and control (n=4). C) Western blot showing protein for the different sizes of the 
GLP-1 receptor and V5 epitope. D) No difference in expression of 49kD GLP-1R 
(n=4). E) V5 epitope indicates that infection did work and was contributing to 
GLP-1R expression, but did not increase overall expression as indicated by A 
and C. nsp>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.2: Immunohistochemistry of the GLP-1 receptor expression on 
C57B6 mouse aortic endothelial cells. Antibody: Santa Cruz GLP-1R (H-55) 
SC-66911- 1:50 dilution.  
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Figure 3.3: Db/db and db/+ adipose tissue immunohistochemistry for 
GLP-1R and GLP-1 has anti-inflammatory effect on monocytes. A) 
Immunohistochemistry of adipose tissue from db/+ non-diabetic mice and db/db 
diabetic mice shows GLP-1R staining in the crown-like structures of the db/db 
mice. This staining co-localized with the immunofluorescent staining of mac-2 for 
macrophages (red) and also shows fat cell nuclei marker (blue) in the db/db 
mice. B) Pre-incubation of monocytes with GLP-1 reduced adhesion capacity. 
HAECs were incubated with 10ng/mL TNFα to induce expression of cellular 
adhesion molecules then THP-1 monocytes pre-incubated with 30pM GLP-1 
were added. Reduced adhesion indicates a direct effect of GLP-1 on THP-1 
monocytes (n=6). nsp>0.05, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.4: HAEC and C57BL6 mouse endothelial and pancreatic 
DPP4 expression. A) DPP4 RTPCR product of expected weight. B) Western 
blot of HAECs and DPP4 protein expression. C) Immunohistochemistry (IHC) of 
aorta from C57B6 mouse for DPP4. D) IHC of pancreatic islets from C57B6 
mouse. IHC experiments used DPP4/CD26 (H-270) SC-9153 antibody from 
Santa Cruz.  
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Figure 3.5: High glucose increases DPP4 activity. A) Exposing HAECs 
to high glucose (25mM) for one week resulted in increased degradation of 0.6mM 
gly-pro-p-nitroanilide (GPN) quantified after 4hrs incubation with GPN (n=10). B) 
GLP-1 degradation was increased when exposed to HAECs treated with high 
glucose. This effect was inhibited by aprotinin, a serine protease inhibitor. HG: 
25mM glucose, NG: 5mM glucose, A: aprotinin 25µg/mL (n=2). nsp>0.05, 
*p<0.05, **p<0.01, ***p<0.001. 
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CHAPTER 4: Discussion  
The data presented in chapters 1 and 2 discuss the individual roles of 
GLP-1 and GLP-1 synthetic analog, liraglutide, on TNFα or LPS induced 
endothelial dysfunction. The results indicate a similar pattern of anti-inflammatory 
action dependent on calcium induced activation of AMPK (as shown in Figures 
1.6A,C, 2.6A,C). There are, however, noteworthy differences. In the following 
chapter the key signaling differences between GLP-1 and liraglutide and further 
lines of investigation based on these differences are discussed.  
Calcium Signaling 
There are two main sources of calcium from which flux can occur in the 
endothelial cell. The two sources are: mobilization of calcium from intracellular 
stores, mainly the endoplasmic (ER) and sarcoplasmic reticulum (SR), and 
entrance of extracellular calcium through store operated cation channels (SOCs) 
[81]. Mobilization of calcium from intracellular stores results in a rapid spike of 
cytosol calcium concentration and then return to baseline [155]. This has been 
demonstrated in human pulmonary artery endothelial cells (HPAECs) stimulated 
with thrombin in the absence of extracellular calcium [155]. Stimulation of calcium 
influx from extracellular sources results in a more sustained rise in cytosolic 
levels of calcium until it is cleared into the ER, SR or mitochondria. In the same 
HPAECs/thrombin study, addition of calcium to the extracellular medium prior to 
treatment results in a rapid increase and then maintenance of the elevated level 
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of intracellular calcium [155]. This indicates that thrombin affects both 
mechanisms involved in calcium flux. It induces the release of intracellular 
calcium stores, followed by opening transient receptor potential channels 
(TRPC), the essential components of store operated cation channels (SOC) [82] 
to allow in extracellular calcium. Depletion of certain intracellular calcium stores 
has been shown previously to open TRPC as well [83].  
As shown in the previous papers, both GLP-1 and liraglutide stimulate an 
increase in intracellular calcium level. This was measured by an ionoptix 
microscope capable of tracking changes in calcium bound (340nM)/ free (380nM) 
fura-2 excitation over time (Figure 4.1A,B). The treatments stimulated different 
trajectories for increase in intracellular calcium levels (Figure 4.1C,D). Liraglutide 
treatment resulted in a rapid increase, which peaked and then returned to 
baseline (Figure 4.1D). Interestingly this effect appeared to be dose dependent 
as supraphysiological levels of liraglutide resulted in a dose dependent effect on 
the increase in intracellular calcium (Figure 4.1E). GLP-1 treatment resulted in a 
slightly slower S shaped curve rise and then sustained elevation over the course 
of the read (Figure 4.1C). These differences suggest a potential difference in the 
source of calcium, as discussed before.  
If GLP-1 and liraglutide stimulated calcium increase follow the same 
principles as thrombin, the following could be concluded. Liraglutide may 
stimulate the release of intracellular calcium stores exclusively, and GLP-1 may 
stimulate both the release of intracellular calcium stores and the opening of 
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TRPC for extracellular calcium entrance. Stimulation with ionomycin, a calcium 
ionophore which induces the release of calcium from the sarcoplasmic reticulum 
and subsequent activation of SOC [156, 157] resulted in a similar trajectory as 
GLP-1, but greater increase in intracellular calcium level (Figure 4.1F). It has 
been shown that release of intracellular calcium stores can cause different 
effects on SOC calcium entrance, but the reasoning behind these differences is 
unclear [157].  It is possible that GLP-1 stimulates the release of intracellular 
calcium stores linked to SOC/TRPC resulting sustained increase in cytosolic 
calcium, where as liraglutide stimulates a release of a different intracellular 
source not linked to SOC/TRPC resulting in rapid clearance of cytosolic calcium.  
Another potential reason for the difference in calcium trajectory is 
stimulation of different receptors or combinations of receptors. It has been shown 
that GLP-1 receptor knock out mice retain some of the cardiovascular benefits of 
GLP-1 therapy [34]. Interestingly, the knock out does inhibit all the benefits of 
GLP-1 synthetic analog, exendin-4, therapy [34]. Therefore, it is possible that 
GLP-1 stimulates more than just the known GLP-1 receptor, where as GLP-1 
synthetic analogs only target the known receptor. This also may account for the 
difference in intracellular calcium trajectory we observed between GLP-1 and 
liraglutide treatment.   
It may be advantageous that liraglutide stimulates a short-term increase in 
intracellular calcium as its half-life in circulation is twelve hours, in comparison to 
GLP-1, which is two minutes. Sustained activation of a signaling pathway is not 
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necessarily advantageous, but pulsate activation, like that from exercise on 
AMPK has been shown to be beneficial in the endothelium [158]. Since GLP-1 
would degrade quickly in circulation, the likelihood that it would re-circulate and 
activate calcium flux, and downstream AMPK, again is unlikely. Liraglutide, 
however, would be in circulation much longer, allowing reactivation to occur. 
Therefore, having a rapid return to baseline may be important to preventing 
negative side effects of sustained elevated calcium levels.  
cAMP Signaling  
 Incretin actions have been attributed to many different signaling 
mechanisms, depending on tissue or cell type. In human beta cells, GLP-1 
stimulation was shown to increase intracellular calcium levels through a cAMP 
dependent mechanism [159]. In addition to potential differences within the 
described signaling mechanism (Figure 4.2), like those observed with calcium 
trajectory, GLP-1 and liraglutide may differ in cascades activated in endothelial 
cells. As shown in figure 4.3 neither physiological (30pM), nor supraphysiological 
(300pM), levels of GLP-1 resulted in an increase in cellular cAMP level in 
HAECs. Interestingly, treatment with liraglutide did result in changes in cAMP 
level. 100nM liraglutide resulted in a small, but significant, increase in cAMP, 
whereas suprapharmacological 1000nM treatment resulted in a much greater 
increase in cAMP level (Figure 4.3). This difference in cAMP signaling is notable 
for two reasons; first, cAMP affects many downstream signaling mechanisms that 
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may result in unique effects of liraglutide, and second, that there is a significant 
dose dependent effect. 
Although cAMP has been implicated as important in GLP-1 and synthetic 
analog signaling in numerous other cell types, many cAMP independent 
mechanisms have also been described. Of particular relevance, a portion of the 
anti-inflammatory effect of GLP-1 signaling in hepatocytes was shown to be 
independent of cAMP, and dependent on AMPK activation [140]. The effects 
observed in hepatocytes are similar to what we describe in HAECs. These 
results provide additional evidence that although some of the mechanisms of 
GLP-1 and liraglutide overlap, there are distinct differences. Additionally, this 
data indicates the importance of using physiologically relevant concentrations of 
GLP-1 and liraglutide and relevant cell culture models in order to see what is 
most likely to be occurring in vivo.  
 This is the first evidence that liraglutide may stimulate unique cellular 
signaling mechanisms not activated by endogenous GLP-1. cAMP is a common 
second messenger for many cascades involved in regulation of cellular 
processes. Specifically pertaining to atherogenesis, the activation of cAMP, and 
subsequently, PKA, has been shown to inhibit leukocyte transendothelial 
migration, reduce barrier hyperpermeability, and affect cell-cell contact (as 
reviewed in [160]). Although we show that the anti-inflammatory effects of 
liraglutide are dependent on calcium induced activation of AMPK, due to the fact 
that STO-609 and knock-down of AMPK inhibit these effects, it is possible that 
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activation of cAMP further contributes in vivo. Additionally, higher concentrations 
of liraglutide may confer a stronger anti-inflammatory effect due to the apparent 
dose effect on the activation of cAMP and intracellular calcium levels.  
 The observation that GLP-1 and liraglutide may activate different signaling 
mechanisms has both research and clinical implications. First, in research, these 
results emphasize that mechanisms resulting from GLP-1 synthetic analog 
treatments may not reflect the effects of endogenous GLP-1. Also, GLP-1 may 
interact with receptors in addition to the recognized GLP-1 receptor. This could 
result in additional effects of GLP-1 not activated by synthetic analogs. In clinical 
treatment, determining if use of a DPP4 inhibitor to increase endogenous GLP-1, 
or a GLP-1 synthetic analog, will be more effective at reaching treatment goals 
may require more analysis. Additionally, some patients may benefit from both 
increasing endogenous GLP-1 levels through use of a DPP4 inhibitor and use of 
a GLP-1 synthetic analog. Finally, it may be clinically advantageous to extend 
trials of liraglutide to include higher doses to test for tolerance and magnitude of 
effect in chronic and acute treatment protocols.  
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Figure 4.1: GLP-1 (10pM) and liraglutide (100nM) significantly 
increase intracellular calcium, but the trajectories differ. Prior to the addition 
of GLP-1 or liraglutide, HAECs were treated with Fura-2, an indicator of 
intracellular calcium change. A) Change in intracellular calcium from baseline 
(between 240-284secs) to peak stimulation (1380-1424 seconds) after 10pM 
GLP-1 stimulation (n=12). B) Change in intracellular calcium baseline (236-256 
seconds) to peak stimulation (628-648 seconds) after 100nM liraglutide treatment 
(n=21) C) HAECs were exposed to 10nM GLP-1 at 321 seconds and tracked 
until 2000 seconds (N=9). D) HAECs were exposed to 100nM liraglutide at 317 
seconds and tracked 800 seconds (n=21). E) Supraphysiological levels of 
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liraglutide result in greater increase in intracellular calcium change (n=33). F) 
HAECs were tracked until 2000 when 1uM ionomycin was added to release all 
intracellular calcium storage from the endoplasmic reticulum (n=21). nsp>0.05, 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 4.2: Potential signaling cascade for liraglutide and GLP-1 in human 
aortic endothelial cells 
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Figure 4.3: Liraglutide but not GLP-1 increases intracellular cAMP. 
Effect of 3 minute incubation with 30pM GLP-1, 300pM GLP-1, 100nM liraglutide 
or 1000nM liraglutide on cAMP levels in HAECs (n=10). nsp>0.05, *p<0.05, 
**p<0.01, ***p<0.001.  
 
 
 
 
 
115 
APPENDIX 1: Efficacy and Adverse Events  
Review of incretin synthetic analog adverse event reports 
 As a relatively new class of therapy, the risks for adverse events 
associated with incretin synthetic analog therapies are still being determined. 
Although current reports conclude that benefits of incretin based therapies far 
outweigh the potential risks [161], large scale prospective studies are still in 
progress. There are multiple prospective studies on GLP-1 receptor agonists and 
DPP4 inhibitors underway. These include; liraglutide in the LEADER trial 
expected to complete in 2016, exenatide in the EXCEL trial expected to complete 
in 2017, and for DPP4 inhibitors; Sitagliptin (TECOS in 2014), Saxagliptin 
(SAVOR-TIMI 53 in 2015), Alogliptin (EXAMINE in 2014), and Linagliptin 
(CAROLINA in 2018) [161]. Therefore, a more conclusive analysis of the adverse 
events associated with this class of treatment will be available in the coming 
years. In the following section we review the initial warnings and current risk 
analysis for GLP-1 synthetic analogs.  
Efficacy of GLP-1 synthetic analog in comparison to metformin or 
sulfonylurea treatment 
 The results from the first two years of the liraglutide effect and action in 
diabetes (LEAD) trial showed that liraglutide improved HbA1c, weight loss and 
risk of hypoglycemia. Specifically, liraglutide significantly decreased HbA1c 
(0.4% with 0.6mg/day dosage and 0.6% with 1.2mg and 1.8mg) in comparison to 
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a 0.3% increase with metformin monotherapy [162]. Although HbA1c decrease 
with liraglutide was found to be non-inferior in comparison to the 0.5% decrease 
with sulfonylurea, glimepiride. Patients treated with liraglutide had significant 
weight loss. Liraglutide induced weight loss averaged 2.1kg with the 0.6mg dose, 
3.0kg with 1.2mg and 2.9kg with 1.8 mg, compared to the weight gain (0.7 kg) 
that occurred in patients treated with glimepiride [162]. Overall gastrointestinal 
events were more common than with glimepiride or metformin monotherapy, but 
occurrence decreased with time [162]. Additionally, weight loss with liraglutide 
doses 1.2mg and 1.8mg was significantly greater than with metformin 
monotherapy. Hypoglycemia is one of the most significant issues in diabetes 
treatment. Liraglutide had a less than 5.0% occurrence in all dosages, which was 
significantly less than the 24% in patients treated with glimepiride. Overall, the 
LEAD trial results suggest that liraglutide as a monotherapy has significant 
benefits above and beyond metformin and glimepiride on diabetes control.  
Potential effect of GLP-1 synthetic analogs or DPP4 inhibitors on 
pancreatitis and pancreatic cancer risk 
 Although there was early speculation that GLP-1 synthetic analogs raised 
pancreatitis and pancreatic cancer risk, larger studies do not support this 
preliminary conclusion. Diabetes itself results in a significant increase in risk for 
both acute and severe acute pancreatitis [163] and pancreatic cancer [164]. A 
prospective cohort within the Optum Research Database of national commercial 
health insurance claims showed that use of liraglutide, exenatide or DPP4 
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inhibitors did not increase the instance of acute pancreatitis in comparison to a 
pooling of patients on comparator drugs [165]. Interestingly, although statistically 
insignificant, pioglitazone had the highest incidence rate per 100,000 person 
years. Pancreatic cancer incidence was not significantly different in patients 
treated with liraglutide, exenatide or DPP4 inhibitors in comparison to pooled 
comparator drugs as well. Pooled sulfonylureas, however, had an almost 
significant increase in pancreatic cancer incidence rate/100,000 person years 
[165]. Therefore, diabetes increases the risk of pancreatitis and pancreatic 
cancer above healthy controls, but treatment with GLP-1 synthetic analogs or 
DPP4 inhibitors does not increase this risk further.  
GLP-1 synthetic analogs and thyroid cancer risk  
 GLP-1 synthetic analogs were shown to increase calcitonin secretion and 
stimulate C-cell hyperplasia and neoplasia in rats and mice. C-cell proliferation 
and neoplasia, however, have not been documented in nonhuman primates or 
humans. Therefore, the proliferative C-cell effects may be rodent-specific [166]. 
Furthermore, analysis of calcitonin levels in several thousands of subjects did not 
indicate a relationship between GLP-1 synthetic analog liraglutide and plasma 
calcitonin. Currently, no cases of medullary thyroid cancer have been attributed 
to taking liraglutide [167]. Due to the rarity of this condition it is still important to 
be aware of this potential risk and monitor it in large-scale studies, but risk 
appears to be limited to rodents.  
118 
CONCLUSION 
 Recent epidemiological and clinical evidence suggests that GLP-1 
synthetic analog therapies confer a cardiovascular disease risk benefit to type 
two diabetic patients. When this study began, it was unknown if this benefit was 
solely due to improvements in glucose control, weight loss and anti-inflammatory 
effects on the liver, or if a cardiovascular specific component was involved. The 
purpose of this study was to determine if GLP-1 and GLP-1 synthetic analog, 
liraglutide, have a direct effect on endothelial cells which could contribute to the 
observed cardiovascular risk reduction in patients. The previous studies provide 
evidence for an endothelial cell specific cardiovascular effect of both GLP-1 and 
liraglutide.  Mainly, both inhibit inflammation stimulated by TNFα and LPS 
through a novel signaling mechanism in human aortic endothelial cells (HAECs).  
The anti-inflammatory effects were demonstrated by inhibition of TNFα and LPS 
stimulated transcription and translation of cellular adhesion molecules and 
adhesion of THP-1 monocytes by GLP-1 and liraglutide. The novel signaling 
mechanism found to be responsible for these effects is dependent on influx of 
calcium resulting in the activation of CaMKKβ and AMPK. Together, this data 
indicates that GLP-1 and synthetic analog liraglutide could act in vivo to inhibit 
endothelial inflammation and dysfunction, an early event in atherogenesis. This 
may contribute to the reduction in cardiovascular disease risk observed in 
patients on GLP-1 synthetic analog therapies. If, future data for testing this effect 
in vivo indicates that the cellular signaling cascade and effects observed here in 
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vitro occur in vivo, this would support increasing the efficacy from a type two 
diabetes treatment to a treatment for cardiovascular risk reduction.    
FUTURE DIRECTIONS  
Although the major contributions of this thesis are the data on the 
endothelial cell specific anti-inflammatory effects of both GLP-1 and liraglutide 
and the mechanism responsible, another contribution is the differential effects of 
these two treatments. In comparing the results from the two, it becomes clear 
that they do not have exactly the same function. Therefore, future studies could 
be done to clarify the extent of these differences. This would involve comparing 
the effects and signaling mechanism of the multiple different GLP-1 receptor 
agonists available against that of GLP-1. Expanding this would include repeating 
and expanding the studies performed in the previous papers in HAECs, beta 
cells, hepatocytes and other cells shown to respond to GLP-1/receptor agonists. 
One area of expansion pertaining to this direction is that our data suggests that 
high dose liraglutide induced effects above and beyond those found at 
concentrations reached in vivo. This highlights the potential dose effect of 
synthetic analog therapies, and indicates that this should be accounted for or 
acknowledged in future studies.  
In addition to the observed anti-inflammatory effects of GLP-1 and 
liraglutide which could provide potential cardiovascular benefit there are other 
endothelial cell specific changes that may also occur and add to this effect. For 
example, increasing nitric oxide synthesis and anti-apoptotic effects could also 
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improve cardiovascular risk. Generation of nitric oxide would be interesting to 
measure as we found that AMPK activation resulted in phosphorylation of eNOS. 
This phosphorylation and activation of eNOS has been shown in other studies to 
result in increased nitric oxide generation in endothelial cells [168]. Increased NO 
has also been shown to have anti-inflammatory effects [58] further indicating that 
more studies should be done on its involvement in the effects observed here. 
Endothelial cell apoptosis is also implicated in the pathogenesis of 
atherosclerosis and cardiovascular diseases [169]. GLP-1 and synthetic analog 
therapies have been previously shown to inhibit beta cell apoptosis [170], 
therefore, it would be interesting to see if it acts in similar ways in endothelial 
cells. Determining the potential effects of GLP-1 and/or GLP-1 synthetic analogs 
on endothelial cell nitric oxide production and apoptosis would create a more 
complete profile on the endothelial specific effects of the treatments.   
In the next few years, many large scale prospective trials will conclude 
allowing for clarification of correlative and causative effects of GLP-1 synthetic 
analog therapies on diabetes, metabolic disease and cardiovascular disease. If 
the data from these prospective trials confirm the preliminary retrospective trials 
and in vitro data, in support of GLP-1 synthetic analog therapies conferring a 
cardioprotective benefit, a future direction would be to increase the efficacy of 
this treatment. This would involve testing its long-term preventative capacities in 
patients with high risk for cardiovascular disease, genetic, metabolic or 
otherwise.  
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Overall, the future direction for GLP-1 and synthetic analog research are 
two fold. In vitro data indicates that GLP-1 and the synthetic analogs have a 
cardiovascular specific effect, the extent of this effect, the difference between the 
synthetic analogs and GLP-1 and the dose at which these effects occur, all 
warrant more in depth investigation. In vivo it is clear that they have many 
different tissue specific effects all of which appear to be protective for the 
comorbidities of obesity and diabetes. The efficacy of GLP-1 synthetic analog 
therapies as a way to treat these comorbidities requires more detailed 
prospective analysis.  
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